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8General introduction
In 1954, Andrew Hunt and others reported on a child with a severe convulsive disorder who 
responded to regular administration of pyridoxine (vitamin B6)1. The authors preferred the 
term ‘pyridoxine dependency’ instead of ‘pyridoxine deficiency’ and they hypothesized that 
a metabolic anomaly of pyridoxine metabolism was present in this patient.
Pyridoxine Dependent Epilepsy (PDE) is a very rare disease with a reported incidence of 
1:783 000 in Great Britain and of 1:250 000 in the Netherlands2,3. In PDE seizures start in 
utero as 20 - 25% of the mothers perceive abnormal foetal movements during pregnancy, 
or seizures start at birth or soon after birth. Seizures can start even months after birth. In 
PDE other non-convulsive clinical symptoms than seizures can be observed4. These non-
convulsive symptoms indicate that PDE is essentially an encephalopathy with epilepsy as 
the most dominant symptom. 
For decades there was great uncertainty among doctors how to identify or to exclude PDE 
in patients with therapy resistant seizures. The reasons for this dilemma were several; 
i.e. the great clinical heterogeneity and the age of presentation of seizures, the variety 
of clinical symptoms and the rarity of PDE, and because the metabolic defect remained 
unclear for half a century. Another reason was that in children with seizures with or without 
PDE additional therapeutic effects of pyridoxine can be seen. This dilemma might explain 
the use of terms as classical PDE, non-classical PDE, pyridoxine dependent, pyridoxine 
responsive, pyridoxine deficient, possible PDE, probable PDE and definite PDE which were 
used in the past.
For many years scientists focused their research in PDE patients on a metabolic defect in 
the GABA synthesis pathway in which pyridoxine acts as a cofactor. However a metabolic 
defect in GABA metabolism could never be demonstrated. In 1998 a locus for PDE on 
chromosome 5q31 was suggested but the disease relating gene could not be identified5. 
Plecko reported elevated plasma and cerebrospinal fluid levels of pipecolic acid in 2000 
but the significance of this remained unanswered6. In 2006 a British-Dutch consortium 
(Research leaders Peter Clayton and Cornelis Jakobs) discovered that the metabolic defect 
of PDE is based on a disorder in lysine metabolism7. Furthermore mutations were found 
in the ALDH7A1 gene, also known as the antiquitin gene, which is indeed located on 
chromosome 5q31.
Prior and independently from these findings, the epidemiology of PDE in the Netherlands was 
reported in 2005 (Jasper Been and Levinus Bok)3. This study based on clinical definitions 
presented 11 PDE patients with a calculated birth incidence of PDE in the Netherlands of 
1:252 000 newborns. 
In 2006, two Dutch groups, under the leadership of Prof. Dr Cornelis Jakobs, Metabolic 
Unit, Department of Clinical Chemistry, VU University Medical Centre, Amsterdam and Prof 
Dr Michèl Willemsen, Department of Pediatric Neurology, Radboud University Nijmegen-
Medical Centre, Nijmegen, collaborated on a PDE research project. Since 2006 the number 
of PDE patients in the Netherlands increased from 11 (based on clinical definition) to 22 
Chapter I.a
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9patients (metabolic and genetically confirmed). The studies – as described here – aim to 
investigate epidemiological, biochemical, molecular genetic and clinical aspects of PDE. 
Many other scientists, doctors and hospitals collaborated in these studies as all patients are 
from all regions of the Netherlands. We thank all who cooperated in these studies.
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Abstract
Introduction: Pyridoxine-dependent epilepsy is a rare cause of seizures in childhood. 
The diagnosis is made upon clinical criteria, that in many cases are never met. Therefore, 
epidemiologic data on pyridoxine dependency are scarce.
Objectives: To study the epidemiology of pyridoxine dependent epilepsy in the Netherlands, 
and to determine whether the diagnosis is based upon the appropriate criteria.
Methods: Nationwide all departments of paediatrics (n = 113) and of paediatric or neonatal 
neurology (n = 17) were asked to report cases of pyridoxine-dependent seizures. Birth 
incidences were calculated using national data on live births from 1991 to 2003.
Results: Response was received from 67% of paediatric departments, including all university 
hospitals and 94% of child neurology departments. Thirteen patients were reported. Four 
definite (31%), three probable (23%), and four possible cases (31%) were identified. 
Two cases (15%) did not meet criteria for either of these groups. The birth incidence was 
1:396 000 for definite and probable cases and 1:252 000 when possible cases are included.
Conclusions: Thus far, epidemiologic data on pyridoxine dependent seizures were only 
available from the UK and Ireland. A higher incidence was found in the Netherlands, 
in accordance to earlier suggestions of a regional difference. The study shows that the 
diagnosis is often made without performance of a formal trial of withdrawal. We want to 
underline the importance of confirming the diagnosis, concerning the consequences as for 
individual prognosis, the potential side effects of prolonged pyridoxine substitution, and 
the possibility of treating the mother in case of future pregnancies.
Chapter I.b
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Introduction
Pyridoxine-dependent epilepsy is a rare autosomal recessive disorder with a classic 
presentation of onset of seizures in the first days of life that are intractable to conventional 
anti-epileptics1,2. In pyridoxine dependency, seizures will generally cease several minutes 
after parenteral administration of pyridoxine (vitamin B6). The diagnosis is established 
when convulsions recur after withdrawal of pyridoxine (within days to weeks) and cease 
again after a second trial of pyridoxine2. In general, the patient will be free of seizures 
after institution of pyridoxine maintenance monotherapy. Atypical forms include those 
with seizures only partly responsive to pyridoxine, referred to as pyridoxine-responsive 
seizures, and those with late onset of seizures2.
Few reports have been made of epidemiological data concerning pyridoxine dependency. 
A regional study in the United Kingdom (UK) published in 1996 by Baxter, reported a 
point prevalence of definite cases of 1:100 0003. When the study was extended to the 
UK and Ireland in 1999, a point prevalence of definite and probable cases of 1:687 000 
and a birth incidence of 1:783 000 were found4. These and other observations support 
the presence of a regional variation of the incidence of pyridoxine-dependent seizures3-5. 
It has been suggested that the incidence as reported by Baxter in 1999 is probably an 
underestimation of the true prevalence4-6. Concerning the low prevalence of pyridoxine-
dependent seizures, patients are likely to be underdiagnosed. Moreover, in many cases a 
formal trial of pyridoxine withdrawal, required for establishment of the diagnosis, is never 
performed. The need for additional demographic studies of pyridoxine-dependent seizures 
has been recognised5, yet up to date none have been performed.
 
The aims of this study were 1) to study the epidemiology of pyridoxine-dependent seizures 
in the Netherlands (total population January 1st 2004: 16 258 000); and 2) to determine 
whether the diagnosis is based upon the appropriate clinical criteria.
Methods
A questionnaire by letter was sent to all heads of paediatric departments in the Netherlands, 
whom were asked to report any case of pyridoxine-dependent seizures born between 
1980 and 2003. Likewise, all paediatric neurologists and neonatologists of the neonatal 
neurology working group were individually approached to report cases. Respondents were 
asked to fill out a questionnaire. The referred data were reported and stored anonymously, 
for which no ethical approval is necessary in the Netherlands. The criteria of definite, 
probable, and possible cases of pyridoxine-dependent seizures were applied as published 
by Baxter in 19994. Birth incidences were calculated over the period of January 1991 to 
December 2003, using the total number of life births in the Netherlands during this period 
as adapted from http://statline.cbs.nl.
Epidemiology of pyridoxine-dependent seizures in the Netherlands
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Results
Response was obtained from 76 of 113 paediatric departments (67%), including all 
university hospitals (n = 8) and from 16 of 17 departments of paediatric and/or neonatal 
neurology (94%). Eighteen notifications of known pyridoxine-dependent cases were 
received, including five duplicate reports. Each patient was at least reported by one academic 
specialist or child neurologist. In addition, one patient from our personal experience was 
included (patient 10 in table I).
Of all patients reported only one was born before 1991. Also, this was one of two patients 
of whom only sparse clinical data were retrieved. Many respondents mentioned difficulty 
reporting patients or retrieving clinical data from several years ago. Therefore, we decided 
to limit the period down to patients born between January 1991 and December 2003, 
as mentioned previously. Thus, 13 patients were included in total, one of whom has 
previously been reported (patient 3)7. The total number of live births during this period was 
2 771 397.
Four patients (31%) met the criteria for definite pyridoxine-dependent seizures. Three 
probable cases (23%) and four possible cases (31%) were defined. The birth incidence of 
definite and probable cases was 1:396 000. When possible cases are included, the birth 
incidence was 1:252 000.
Two patients (15%) did not meet the criteria for either definite, probable, or possible 
pyridoxine dependency. One patient had seizures responsive to pyridoxine and was initially 
diagnosed with pyridoxine dependency after a trial of withdrawal had been carried out. Yet 
one week after the trial, seizures recurred and became unresponsive to pyridoxine. At age 
5 months, folinic acid was added to his treatment regimen. Analysis of the cerebrospinal 
fluid (CSF) showed the presence of the typical marker for folinic acid-responsive seizures. 
Yet despite extensive anti-epileptic therapy including pyridoxine and folinic acid, the patient 
still is not fully seizure-free.
The second patient had seizures directly after birth that responded clinically, but not 
electrophysiologically to pyridoxine. A trial of withdrawal was never performed, and she 
had never been seizure-free on pyridoxine monotherapy. Interestingly, intrauterine seizures 
had been present in this patient, while in contrast only one definite case was reported to 
have had intrauterine seizures.
The characteristics of the reported patients are summarised in table I. Two probable 
cases each had a sibling with definite pyridoxine dependency (patients 6 and 7). Also, two 
possible cases were sisters (patients 1 and 5). Only few clinical data on patient 6 were 
available. Nevertheless, this patient was included since she was a sister of patient 4. She 
had seizures responding to pyridoxine and has been seizure-free on pyridoxine, however 
no trial of withdrawal has been performed. Reports of gender and race of the patients and 
consanguinity of the parents were incomplete.
Signs of fetal distress, e.g. meconium stained amniotic fluid or abnormal cardiotocography, 
Chapter I.b
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had been present in two definite and two possible cases (patients 3 and 10, 5 and 8 
respectively). Patient 5 experienced an episode of persistent pulmonary hypertension and 
suffered perinatal asphyxia with signs of cerebral ischemia on ultrasonography. Convulsions 
in this patient were initially ascribed to hypoxic-ischemic encephalopathy. Yet, since her 
sister had previously experienced neonatal seizures responsive to pyridoxine, pyridoxine 
was administered. On this, seizures ceased, and electroencephalography normalised. Both 
girls are currently seizure free on pyridoxine monotherapy, yet in neither one a trial of 
withdrawal has been performed.
Discussion
Thus far, epidemiological data on pyridoxine-dependent seizures were only available from 
the UK and Ireland. As reported in this paper, a higher incidence of possible, probable, and 
definite pyridoxine-dependent cases was found in the Netherlands. This is in accordance 
with previous reports of a regional difference in the prevalence of pyridoxine-dependent 
seizures. The relative proportion of definite, probable, and possible cases in our study was 
36%, 27%, and 36%, respectively. These percentages are very similar to those reported by 
Baxter: 39%, 25%, and 36%, respectively4. Therefore, regional differences in diagnostic 
skills are unlikely to account for the different incidences between the two studies. A genetic 
factor is likely to play an important role, since there were three sibling cases in our small 
study.
Moreover, our study confirms that the diagnosis is often being made without application 
of the appropriate clinical criteria. Of all thirteen patients reported, eight (62%) had been 
diagnosed with pyridoxine-dependent seizures without the formal trial of withdrawal having 
been carried out. Parents may be reluctant to a trial of pyridoxine withdrawal, because they 
fear it will cause harm to the child1. On the other hand, we believe that in many cases 
physicians may never consider a trial of withdrawal due to insufficient knowledge of this 
rare disorder. A standardised therapeutic approach to neonatal seizures has previously been 
suggested to increase the awareness and improve the recognition of classical pyridoxine-
dependent seizures5. In the Netherlands, a treatment protocol including a pyridoxine trial 
is increasingly used to address neonatal seizures in a standardised manner. We believe that 
this will indeed increase the recognition of pyridoxine-dependent seizures and support an 
appropriate establishment of the diagnosis. Such an approach should advice administration 
of parenteral pyridoxine 50 - 100 mg as a test dose in neonates with seizures intractable 
to conventional anti-epileptics. Clinicians should be aware of possible cardiorespiratory 
depressive effects of a first pyridoxine administration. Recently, there have been promising 
reports on pipecolic acid being a possible diagnostic marker of pyridoxine-dependent 
seizures8,9. It has even been suggested that measurement of pipecolic acid may be 
sufficiently sensitive to replace a trial of withdrawal9. Therefore, we think measurement of 
pipecolic acid in plasma and/or CSF should be included in such a protocol as well. Additional 
data on this issue need to be collected in order to clearly establish the value of pipecolic 
acid in the diagnosis of pyridoxine-dependency. Unfortunately, no data are available on 
pipecolic acid measurements in the patients reported here. 
Chapter I.b
Boek_VB_bruin.indd   16 3-7-2013   20:50:13
17
Confirmation of the diagnosis is reassuring for the patient and his or her family and is of 
great importance. It may have consequences for genetic counselling and facilitates a more 
precise prognosis. Furthermore, confirmation of the diagnosis in a young child may warrant 
pyridoxine administration to the mother in case of a future pregnancy, which in turn may 
prevent developmental delay in a subsequent pyridoxine-dependent child10. On the other 
hand, a trial of withdrawal may identify patients who have wrongfully been diagnosed 
with pyridoxine dependency. Previous data have shown that a large minority of patients 
treated as having pyridoxine-dependent seizures in fact remain permanently seizure-free 
after pyridoxine withdrawal4. This is important since needless maintenance treatment with 
high doses of pyridoxine may cause a serious, although largely reversible, dorsal root 
gangliopathy11. No hard data are available as to what would be the proper timing for a 
trial of withdrawal. Probably it is better not to perform a trial shortly after the initiation of 
pyridoxine supplementation. Baxter has advocated the trial to be carried out before school 
entry, i.e. around the age of four years1.
All patients reported in this study had relatively early onset of seizures, while the initial 
presentation of pyridoxine-dependent seizures may occur up to the age of 9 months. 
This may be due to both underreporting and underrecognition of late-onset pyridoxine 
dependency. Early-onset seizures in pyridoxine dependency are known to be associated with 
a poorer outcome, especially when treatment initiation is delayed12. In our study however, 
only half of all patients were reported to have a substantial degree of developmental delay. 
Also there was no clear correlation between the age of treatment and outcome. Earlier 
reports on this issue have been conflicting. Baxter and Aicardi have suggested that earlier 
pyridoxine treatment is beneficial, and this has been confirmed by Plecko et al., whereas 
Haenggeli et al. found no correlation between the time of treatment and outcome2,8,12. 
Conclusions are to be drawn with caution however, since the number of patients is relatively 
small, and comparative performance tests have not been performed.
The data presented in this study are based upon the cooperation of the clinicians addressed. 
A methodological limitation of the study is related to the retrospective character of the 
study. Therefore, cases of pyridoxine-dependent patients may be missed due to lack of 
response, leading to an underestimation of the actual incidence. Overall the response was 
limited, yet virtually all university hospitals and neurological departments replied. Since 
each patient was reported by at least one of the latter, we believe an incomplete report of 
patients is not very likely. Unfortunately, our study period had to be narrowed due to the 
inability of many respondents to retrieve clinical data from several years back. Theoretically 
this may have caused a reduced report of patients as well, although the relatively even 
birth year distribution of the reported patients over time does not support this. On the 
other hand, the high number of sibling cases may have led to an overestimation of the 
incidence of pyridoxine-dependent epilepsy.
In conclusion, we think our data are indicative of a reliable number of patients born between 
1991 and 2003 who are believed to be pyridoxine-dependent in the Netherlands. Pyridoxine 
dependency seems to be more prevalent in the Netherlands than in the UK and Ireland, 
supporting earlier suggestions of a regional variation in the demographics of pyridoxine 
dependency. However our results confirm that still the diagnosis is regularly made without 
Epidemiology of pyridoxine-dependent seizures in the Netherlands
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application of the appropriate clinical criteria. On the other hand, many patients may never 
have been recognised and may continue to be unsuccessfully treated with conventional 
anti-epileptics. A better knowledge of the disease entity and the clinical criteria needed for 
establishment of the diagnosis will contribute to heightened awareness and more adequate 
management of potentially pyridoxine-dependent seizures. A standardised treatment 
protocol for neonatal seizures including a pyridoxine trial may be of additional value, at 
least as long as pyridoxine-dependent epilepsy remains a clinical diagnosis.
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Abstract
Background: Pyridoxine Dependent Seizures (PDS) is a rare, autosomal recessively 
inherited disorder. Recently α-aminoadipic semialdehyde (α-AASA) dehydrogenase 
deficiency was identified as a major cause of PDS, which causes accumulation of both 
α-AASA and pipecolic acid (PA) in body fluids. 
Methods: We studied urinary and plasma α-AASA and PA levels in 12 Dutch clinically 
diagnosed PDS patients.
Results: α-AASA was elevated in both urine and plasma in 10 patients. In these patients 
plasma PA levels were also elevated but urinary PA levels were normal. 
Discussion: In all patients with clinically definite PDS, and in most patients with probable or 
possible PDS, the clinical diagnosis of PDS could be confirmed at the metabolite level. Non-
invasive, urinary screening for α-AASA accumulation provides a reliable tool to diagnose 
PDS and can save these patients from the classical and potentially dangerous pyridoxine 
withdrawal test to prove PDS.
What is already known on this topic
• PDS is a rare disease caused by alpha-aminoadipic semialdehyde (α-AASA) 
 dehydrogenase deficiency.
• Epidemilogical data on PDS are rare and are based on clinical criteria for PDS.
What this study adds
• Non-invasive, urinary screening for α-AASA accumulation provides a reliable tool to 
 diagnose PDS.
• The birth incidence on metabolic confirmed PDS of this nationwide dutch study is 
 estimated to be at least 1:276 000.
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Introduction
Pyridoxine dependent seizures (PDS) is a rare, autosomal recessively inherited disorder 
usually presenting very shortly after birth and in some cases in the womb. For 50 years 
PDS has been a clinical and biochemical conundrum which has puzzled physicians 
and scientists1. Plecko et al and Willemsen et al observed isolated pipecolic acid (PA) 
elevations in plasma and cerebrospinal fluid in PDS patients, yet the biochemical relation 
with pyridoxine metabolism remained unclear2-4. Recently, α-aminoadipic semialdehyde 
(α-AASA) dehydrogenase deficiency due to pathogenic mutations in the ALDH7A1 gene, 
was shown to be a major cause of PDS5. In mammals, the essential amino acid L-lysine 
is degraded via PA into the intermediate α-AASA, which is subsequently oxidized to 
L-2-aminoadipic acid, a reaction catalyzed by the enzyme α-AASA dehydrogenase 
(EC 1.2.1.31, also named antiquitin)(Fig. I). In PDS patients the lack of α-AASA 
dehydrogenase leads to an accumulation of α-AASA and PA in body fluids. α-AASA is in 
spontaneous reversible equilibrium with piperideine-6-carboxylate (P6C) in the cytosol. 
Accumulated P6C irreversibly reacts with active pyridoxine, ie, pyridoxal-5-phosphate 
(P5P), by forming a Knoevenagel condensation product (Fig. II). This irreversible reaction 
causes a secondary deficit of P5P in affected children, which subsequently leads to 
epileptic seizures. Restoration of the P5P pool can easily be achieved by oral pyridoxine 
supplementation, and resolves the seizures. 
Recently we reported on the epidemiology and clinical features of PDS in the Netherlands 
in this journal6. In that paper the classical clinical criteria according to Baxter were used 
to establish the diagnosis of PDS. We therefore reevaluated that series of PDS patients by 
measuring their levels of α-AASA and PA in urine and plasma. 
L-Lysine
Saccharopine
Pipecolic acid
∆1-Piperideine 2-carbocylic acid
2-keto-6-amino caproic acid
Acetyl-CoA
2-Oxioadipic acid
L-2-Aminoadipic acid
L-2-Aminoadipate 6-semialdehyde
∆1-Piperideine 6-carbocylic acid
Pyridoxine-Dependent Seizures in Dutch patients: diagnosis by elevated urinary α-AASA levels
Figure I.  Metabolic pathway of L-Lysine 
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Methods
We re-evaluated all children (n = 11) with a diagnosis of definite, probable or possible PDS 
from a recently described Dutch cohort of 13 patients6. These patients and their parents 
were invited to visit our hospital and were informed about the novel insights into the 
pathophysiology of PDS. All except one patient (patient 11) underwent further diagnostic 
work-up by laboratory investigations of urine and blood. Furthermore, we were able to 
include a recently born sibling of patient 10 in the present study (patient 12).
α-AASA in urine and plasma was measured by liquid chromatography-tandem mass 
spectrometry as previously published5. Quantitative determination of PA in urine and 
plasma was performed by stable isotope dilution gas chromatography-mass spectrometry7. 
Results
Urine and/or blood samples were obtained from 11 patients. The results of α-AASA and 
PA measurements are listed in table I. α-AASA was elevated in urine and plasma of 10 
patients. PA in plasma was elevated in all patients with elevated (plasma and urine) 
α-AASA, while urinary PA concentrations were normal in all patients.
 
Patient Sibling Birth 
Year
PDS 
(Baxter 
criteria)
AASA 
urine 
(mmol/
mol cr.)
AASA 
plasma 
(μmol/L)
PA urine 
(mmol/
mol cr.) 
PA 
plasma 
(μmol/L)
PDS 
(metabolic 
confirmed)
1 5 1991 possible 16 8.0 0.11 6.5 Y
2 1992 definite 4.7 0.9 0.27 5.8 Y
3 7 1992 definite 29 5.7 0.00 4.6 Y
4 6 1992 definite 4.0 1.1 0.02 7.0 Y
5 1 1993 possible 24 5.0 0.11 5.0 Y
6 4 1994 probable 0.2 < 0.2 0.02 2.2 N
7 3 1995 probable 20 5.8 0.01 5.1 Y
8 1998 possible 12 2.4 0.07 5.5 Y
9 2001 definite 9.6 0.8 2.0 22 Y
10 12 2003 probable 39 6.1 0.08 7.8 Y
11 2003 possible N.A. N.A. N.A. N.A. N
12 10 2004 75 5.2 1.37 11 Y
Chapter II.a
• N.A. = not available; Y = yes; N = not
• Control α-AASA concentrations are < 0.2 μmol/l for plasma, and < 1 mmol/mol creatinine for urine. 
• Control values for PA in urine are 0.55 - 24.1 mmol/mol creatinine (< ½ year of age) and 0.01 - 1.54 mmol/
mol creatinine (> ½ year of age).
• For PA in plasma, control values are 3.75 – 10.8 μmol/(< 1 week of age), and 0.7 - 2.46 μmol/l (> 1 week 
of age). 
Table I.
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Discussion
In this study, in all patients with a definite diagnosis of PDS according to the criteria 
published by Baxter8, α-AASA dehydrogenase deficiency could be proven at the metabolite 
level by demonstrating elevated concentrations of α-AASA (plasma and urine) and PA 
(plasma). The diagnosis was also confirmed in two out of three patients with probable PDS 
and in three out of four patients with possible PDS. 
The diagnosis of probable PDS could not be confirmed in one patient (patient 6). She is a 
younger sister of a girl with a definite clinical diagnosis of PDS and metabolic confirmed 
diagnosis of α-AASA dehydrogenase deficiency (patient 4). She had subtle neonatal seizures 
with only minimal epileptic discharges on a 24-hour EEG, which responded to 100 mg of 
pyridoxine given intravenously. She is performing well at school. Her normal development 
makes a diagnosis of PDS even more unlikely since most PDS patients suffer from - at least 
a mild – encephalopathy with learning difficulties5. However, the nature of the neonatal 
seizure-like period remains unexplained. We advised a trial period of pyridoxine withdrawal 
but could not convince the parents to stop pyridoxine treatment. DNA analysis of patients 
included in our study are pending. 
In patient 11, originally diagnosed with possible PDS, pyridoxine was recently withdrawn 
without recurrence of seizures. We consider PDS a very unlikely diagnosis in this patient 
because of the above observation and the fact that the child develops well. The parents did 
not want to cooperate with further metabolic investigations.
In our first report6 we reported two patients (patients 12 and 13 in that paper) who did not 
meet the criteria for either definite, probable of possible PDS. In both patients we have now 
demonstrated normal α-AASA concentrations in plasma and urine, as would be expected 
(data not shown). 
This report is the first nationwide population-based study on metabolic confirmed PDS. 
Our results show that at least 10 children with PDS were born in the Netherlands between 
January 1991 and December 2004. As 2 764 697 children were born in the Netherlands 
during this time (adapted from http://statline.cbs.nl), the birth incidence of biochemical 
proven PDS in the Netherlands is at least 1: 276 000 children. This study further shows 
that most patients, namely 9 out of 11 (82%), were diagnosed correctly using the criteria 
proposed by Baxter. Thus, in circumstances where metabolic examination of α-AASA and/
or PA is not possible, applying the clinical criteria proposed by Baxter seems a reliable 
method to establish a diagnosis of PDS. 
The concentrations of α-AASA and PA, in urine as well as in plasma, vary considerably 
in patients with PDS. A remarkable wide range of α-AASA and PA levels in patients 
has also been found by Mills et al in their very first report on α-AASA dehydrogenase 
deficiency in PDS5. We have no clear explanation for this wide range. Hypothetically it 
might reflect different levels of α-AASA dehydrogenase residual activity, dietary protein 
(L-lysine) intake, or the amount of pyridoxine supplemented. It is tempting to speculate 
that optimum treatment (i.e. pyridoxine dosage) in PDS might be achieved by focusing on 
the concentrations of α-AASA and PA.
Pyridoxine-Dependent Seizures in Dutch patients: diagnosis by elevated urinary α-AASA levels
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Conclusion
Metabolic investigations of urinary concentrations of α-AASA provide a reliable tool to 
prove PDS associated with α-AASA dehydrogenase deficiency at the metabolite level. The 
potentially dangerous trial of withdrawal of pyridoxine, classically used to prove PDS, can 
now be avoided. The novel insights into the pathophysiologic processes that underly PDS 
further provide us with tools to make a better estimation of the true incidence of PDS (in 
this study, for the Netherlands at least 1: 276 000 newborns), and will hopefully lead to an 
optimum treatment regime of this serious neurometabolic disorder. 
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Abstract
The assessment of urinary α-aminoadipic semialdehyde (α-AASA) has become the diagnostic 
laboratory test for pyridoxine dependent seizures (PDS). α-AASA is in spontaneous 
equilibrium with its cyclic form Δ1-piperideine-6-carboxylate (P6C); a molecule with a 
heterocyclic ring structure. Ongoing diagnostic screening and monitoring revealed that 
in some individuals with milder ALDH7A1 variants, and patients co-treated with a lysine 
restricted diet, α-AASA was only modest increased. This prompted us to investigate the 
diagnostic power and added value of the assessment of urinary P6C compared to α-AASA. 
Urine samples were diluted to a creatinine content of 0.1 mmol/L, followed by the addition 
of 0.01 nmol [2H9]pipecolic acid as internal standard (IS) and 5 µL was injected onto 
a Waters C18 T3 HPLC column. Chromatography was performed using water/methanol 
97/3 (v/v) including 0.03 % formic acid by volume with a flow rate of 150 µL/min and 
detection was accomplished in the Multiple Reaction Monitoring mode: P6C: m/z 128.1 > 
82.1; [2H9]pipecolic acid m/z 139.1 > 93.1. Due to the dualistic nature of α-AASA/P6C, and 
the lack of a proper internal standard, the method is semi quantitative. The intra CVs (n = 10) 
for two urine samples of proven PDS patients with only modest P6C increases were 4.7% 
and 8.1%, whereas their inter CVs (n = 10) were 16 and 18% respectively. In all 40 
urine samples from 35 individuals with proven PDS, we detected increased levels of P6C. 
Therefore, we conclude that the diagnostic power of the assessment of urinary P6C and 
α-AASA is comparable.
Chapter II.b
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Introduction
The finding that α-aminoadipic semialdehyde dehydrogenase (α-AASA DH/Antiquitin) 
deficiency is the underlying defect in the vast majority of individuals affected with 
pyridoxine dependent seizures (PDS), has provided the metabolic field with a specific 
biomarker: α-aminoadipic semialdehyde (α-AASA)1-3. Moreover, it has paved the way for 
molecular diagnosis by investigations of the corresponding gene i.e. ALDH7A1. Previously, 
the assessment of pipecolic acid in plasma and cerebrospinal fluid was the only biochemical 
tool for the metabolic laboratories4,5. A drawback of the plasma pipecolic acid assessment 
is that pipecolic acid can also be increased secondary to peroxisome biogenesis disorders 
and/or liver disease6. In our laboratory, we started the measurement of α-AASA in body 
fluids in 20051 (with urine being the preferred matrix), and we have detected in more than 
100 individuals increases of α-AASA. In all cases, when DNA was subsequently sent to our 
laboratory, mutations were detected in the ALDH7A1 gene, illustrating the specificity of the 
α-AASA assessment. Chemically, α-AASA is an interesting molecule, which leads a dualistic 
life, and this might explain why α-AASA was not picked up in the 50 years following 
the first description of PDS7. α-AASA is in spontaneous equilibrium with its cyclic form 
Δ1-piperideine-6-carboxylate (P6C); a molecule with a heterocyclic ring structure (Fig. I). 
We have prepared α-AASA out of commercially available allysine ethylene acetal1, and the 
obtained product is indeed a mixture of both forms: α-AASA and P6C. This dualistic nature 
hampers absolute quantification, however the increases of α-AASA, also when patients 
were on pyridoxine supplementation, were several fold the upper limits of the age-matched 
control population. Ongoing diagnostic screening and monitoring in our laboratory has 
revealed that some individuals with milder ALDH7A1 variants, and patients co-treated with 
a lysine restricted diet, displayed only modest increases.
This prompted us to investigate the diagnostic power and added value of the assessment of 
urinary P6C compared to α-AASA. We have developed a sensitive LC-MS/MS method which 
allowed us to detect P6C in non affected individuals. Urine samples were upfront diluted 
to a creatinine content of 0.1 mmol/L and aliquots were directly injected onto the LC-MS/
MS without the need for derivatisation. Reference values were established and 40 urine 
samples of individuals in which α-AASA was previously found to be increased, were used 
for retrospective P6C quantification.
COOH
O
H
COOH
NH3
H2O
P6C AASA
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Figure I.  Spontaneous equilibrium of P6C and α-AASA
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Material and Methods
Urine specimens
Reference urine samples: The study was approved by the human medical ethics committee 
of Màxima Medical Centre Veldhoven. Reference urine samples (n = 91) were obtained from 
neonates admitted to a level IIIa neonatology intensive care unit (NICU) in Veldhoven, the 
Netherlands. When urine was sampled for standard neonatal care, left over material was 
stored at -20 °C; no additional urine samples were collected for the sole purpose of this 
study. From the patient’s medical records, gestational age, birth weight, actual weight at 
urine sampling, Apgar score, protein intake, medication including anti-epileptic drugs and 
hypothermia treatment were documented. In all these samples α-AASA was assessed and 
found to be within the appropriate reference range. Reference values beyond the neonatal 
period were obtained by analyzing P6C levels in α-AASA negative urine samples which had 
been sent to our laboratory for diagnostic studies. 
Urine samples from PDS patients: In 40 urines, stored at -20 °C, of genetically proven 
and urinary α-AASA positive PDS patients, we have retrospectively determined the 
concentration of P6C. The vast majority of these children were on pyridoxine treatment at 
the time of urine sampling, and in some individual cases, children were co-treated with a 
lysine restricted diet. 
Materials
[2H9]pipecolic acid was purchased from CDN isotopes, Pointe-Clair, Canada. All other 
reagents and solvents were of analytical grade. P6C was prepared out of allysine ethylene 
acetal (Chiralix, the Netherlands) as described before1. 1H-NMR studies of the obtained 
solution showed small amounts of allysine ethylene acetal, in the presence of a complicated 
spectrum of multiplets in the region of 1.5 to 2.5 ppm. The actual concentration of 
α-AASA relative to P6C could not be concluded by the obtained 1H-NMR data. Tandem 
mass spectrometer Q1 scans, in both the negative and positive electrospray ionization 
mode, showed signals corresponding to α-AASA and P6C, and a less abundant signal to 
allysine ethylene acetal (detectable in positive mode). Product ion scans (positive mode) 
of m/z 128.1 (corresponding to the M+1 signal of P6C) yielded two main fragmentation 
products with m/z 82 and m/z 55. Product ion scans (positive mode) of a standard solution 
of pipecolic acid, which can be regarded as the dihydro-analogue of P6C, showed two main 
fragmentation products with m/z 84 and m/z 56. All these combined data confirmed the 
identity of P6C, and we have optimized the LC-MS/MS using the obtained α-AASA/P6C 
reference solution.
P6C sample preparation and LC-MS/MS determination
Urine samples were diluted to a creatinine content of 0.1 mmol/L with solvent A (see below), 
followed by the addition of 0.01 nmol [2H9]pipecolic acid serving as internal standard (IS), 
resulting in a final sample volume of 400 µL. Prepared samples were stable for more than 
1 week at 4 °C. 5 µL was injected onto a Waters C18 T3 HPLC column (150 x 2.1 mm, bead 
size 3.5 µm). Chromatography was performed using solvent A (water/methanol 97/3 (v/v) 
including 0.03 % formic acid by volume) with a flow rate of 150 µL/min. After elution of P6C 
and the IS, the column was rinsed with solvent B (water/methanol 50/50 (v/v) including 
Chapter II.b
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0.03 % formic acid by volume), and was subsequently allowed to regenerate with 100% 
solvent A. Total runtime including regeneration of the column was 7 minutes. The column 
was directly connected to an AB Sciex 4000 QTrap tandem mass spectrometer operating 
in the positive electrospray ionization mode and at optimized settings, and detection was 
accomplished in the Multiple Reaction Monitoring mode. The MRM transitions for P6C were: 
m/z 128.1 > 82.1 (quantifier) and m/z 128.1 > 55.1 (qualifier); the MRM transition for 
[2H9]pipecolic acid was m/z 139.1 > 93.1 . The P6C m/z 128.1 > 82.1 transition and the 
[2H9]pipecolic acid m/z 139.1 > 93.1 transitions correspond to the loss of the carboxyl 
moiety from the molecules. In addition, also the MRM transition for endogenous pipecolic 
acid i.e. m/z 130.1 > 84 was monitored. Results were calculated by directly using the 
obtained P6C/IS and pipecolic acid/IS peak-area ratios. 
Urine spots were prepared by applying 5 µL of urine onto a Guthrie card, after which the 
urine was allowed to dry at room temperature and the spots were stored in the dark at room 
temperature. The edges of the spots were marked with a pencil, cut out by scissors, put in a 
small tube and dissolved in 500 µL of double distilled water. The extraction was stimulated 
by continuous motion of the tube for 30 minutes at room temperature, after which the 
tube were centrifuged at 14000 g and the supernatant was used for P6C quantification. 
The amount of reconstituted urine sample taken into preparations was determined by the 
dilution of the original urine spot relative to the volume of the extraction solvent. α-AASA 
has been assessed by LC-MS/MS as described before1. Briefly, 1 nmol [15N]-α-aminoadipic 
acid (10 μL of aqueous 0.1 mmol/L solution) serving as internal standard, was added to 
10 μL of urine. Subsequently, 100 μL of borate buffer (0.1 mmol/L, pH 10) and 100 μL of 
Fmoc-Cl solution (1.5 mg/ml acetone) were added, samples were mixed vigoursly, and 
allowed to react for 15 minutes at room temperature. 5 μL of the sample was injected onto an 
LC-MS/MS (as for P6C). Chromatography was performed using a Waters X-Terra C18 column 
(150 X 4.6 mm ID; 5 μm particle size) applying a binary linear gradient starting with 
100% solvent A (H2O/ACN 90/10 v/v, containing 125 mg ammonium formate) changing 
to 100% solvent B(H2O/ACN 90/10 v/v, containing 125 mg ammonium formate) in 10 
minutes. Analytes were measured in negative mode using the following transitions: 
m/z -382.1 > -1861 (α-aminoadipic acid); m/z -383.1 > -187.1 ([15N]-α-aminoadipic 
acid); m/z -366.1 > 170.1 (α-AASA quantifier); m/z -366.1 > -144.1 (α-AASA quantifier).
Stability studies
Multiple aliquots of two urine samples of known PDS patients were stored under 3 different 
conditions: 1. at room temperature, 2. in the fridge at 4 °C, and 3. in the freezer at -20 °C. 
The samples were prepared and analyzed over a period of 40 days. Multiple Guthrie card 
spots from urine samples of five known PDS patients were prepared, stored in the dark at 
room temperature, and analyzed over a period of 30 days.
Results
Analytical performance of the LC-MS/MS method
The mass fragmentograms of the LC-MS/MS measurement in urine samples from a PDS 
positive and PDS negative individual are depicted in figure II. P6C elutes at 2.25 minutes 
The measurement of urinary Δ1-piperideine-6-carboxylate, the alter ego of α-AASA, in Antiquitin deficiency
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and [2H9]pipecolic acid at 2.50 minutes. It is important to note that due to the dualistic 
nature of α-AASA/P6C absolute quantification of one or the other is virtually impossible. 
Therefore all quantitative results presented in this study, represent estimations of the 
P6C concentration. For all experiments, we have chosen to use a single point calibration 
for the quantification of P6C, using the known concentration of the internal standard as 
direct reference. We made the assumption that pipecolic acid and P6C have identical mass 
spectrometric characteristics, although we are currently not able to substantiate this.
Assay characteristics
The intra day coefficient of variations (CVs) (n = 10) for two urine samples of two proven 
PDS patients with modest P6C increases were 4.7% (average ± sd: 0.38 ± 0.018 mmol/
mol creatinine) and 8.1% (average ± sd: 0.68 ± 0.055 mmol/mol creatinine) ; the inter day 
CVs (n = 10) for these two urine samples were 16% (average ± sd: 0.35 ± 0.056 mmol/
mol creatinine) and 18% (average ± sd: 0.69 ± 0.13 mmol/mol creatinine) respectively. 
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Figure II.  Mass fragmentograms of the LC-MS/MS measurement of P6C; in the left 
panel: control urine sample (concentration 0.02 mmol/mol creatinine), and in the right 
panel: PDS patient urine sample (concentration 2.05 mmol/mol creatinine). IS represents 
the signal of [2H9]pipecolic acid serving as internal standard.
P6C P6C
P6C
P6C
IS IS
128.1 > 82.1128.1 > 82.1
128.1 > 55.1 128.1 > 55.1
139.1 > 93.1 139.1 > 93.1
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Linearity of the method was examined by multiple dilutions of a positive PDS urine sample 
with a negative urine sample with an identical creatinine concentration. The quantification 
of P6C was linear over the range of 1 to 30-fold dilutions, with absolute P6C concentrations 
ranging from 0.3 µM to 9.3 µM. The limit of detection (S/N ratio = 10) was estimated by 
verifying the P6C peak height relatively to the observed noise at the same chromatographic 
region and was found to be approximately 0.02 mmol/mol creatinine.
The measurement of urinary Δ1-piperideine-6-carboxylate, the alter ego of α-AASA, in Antiquitin deficiency
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Figures IIIA - IIIF.  P6C (A-C) and α-AASA (D-F) levels versus birth weight (grams), 
gestational age (days) and protein intake (grams protein/kg body weight). For all 
correlations: p < 0.05; correlation coefficient R= -0.3 for birth weight and gestational 
age, and correlation coefficient R= +0.3 for protein intake.
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Stability studies
Multiple aliquots of two urines samples have been stored under three conditions. P6C was 
stable in both urines when samples were stored at -20 °C for 40 days. Samples stored at 
4 °C showed clearly that P6C is not stable in this condition with a decrease at 40 days of 
25% in urine sample A and 50% in urine sample B. P6C levels in urines stored at room 
temperature show a dramatic decrease of 75% for urine A to almost 100% in urine B. This 
decline is already notable after 5 days of storage with decreases of approximately 40%. 
P6C levels in urine spots on filter paper, stored in the dark at room temperature showed a 
decline to 50% of the original value after 10 days of storage. 
Urinary P6C and α-AASA reference values
Since PDS often clinically manifest in the neonatal period, 91 urine samples were obtained 
from neonates admitted to a level IIIa NICU in Veldhoven, the Netherlands. Samples 
were directly stored at -20 °C until further analysis. Additionally, 100 urine samples from 
individuals, in which α-AASA was normal (see reference ranges below), were used to obtain 
P6C reference values for all age groups. P6C and α-AASA values in newborns correlated 
positively with protein intake, and negatively with gestational age and body weight 
(Fig. IIIA - IIIF), but there was no correlation of P6C and α-AASA values with any studied 
neonatal IC condition, treatment, or gender. For the whole studied control population, the 
levels of urinary P6C showed a clear age-dependency with P6C levels up to 0.37 mmol/
mol creatinine in the first months of life, decreasing to ≤ 0.05 mmol/mol creatinine for 
children older than 1 year (Fig. IV). We define the following urinary P6C reference ranges: 
≤ 6months: P6C < 0.37 mmol/mol creatinine; > 6 months ≤ 1year: P6C ≤ 0.1 mmol/mol 
creatinine; > 1 year: P6C ≤ 0.05 mmol/mol creatinine. The reference ranges for urinary 
α-AASA are: ≤ 6months: α-AASA < 2 mmol/mol creatinine; > 6 months ≤ 1 year: α-AASA 
≤ 1 mmol/mol creatinine; > 1 year α-AASA ≤ 0.5 mmol/mol creatinine. An overview 
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Figure IV.  P6C levels in reference population
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of the used methodologies for the assessment of both P6C and α-AASA are depicted in 
table I. As our reference population consists of an overrepresentation of premature 
newborns, we recommend other laboratories to in-house establish reference ranges for 
α-AASA and P6C.
Urinary P6C levels in proven PDS patients 
In a unique collection of 40 urine samples from 35 individuals with proven PDS, P6C 
was retrospectively assessed. In all urine samples in which previously α-AASA was found 
to be increased, we detected increased levels of P6C. The observed concentrations of 
P6C were age-dependent. We have depicted all the positive urine samples in figure V, 
illustrating the diagnostic performance of the measurement of urinary P6C. There is a 
strong relationship between the urinary levels of α-AASA and P6C in this cohort of patient 
samples, as is illustrated in figure VI. It is of note that in all these patient samples pipecolic 
acid concentrations were within the appropriate reference ranges.
The measurement of urinary Δ1-piperideine-6-carboxylate, the alter ego of α-AASA, in Antiquitin deficiency
*Concentrations expressed as mmol/mol creatinine; $Pathological range of samples included in this cohort 
(n = 40).
Parameter P6C method α -AASA method
Volume of urine needed < 50 µL 10 µL
Method LC-MS/MS LC-MS/MS
Internal standard [2H9]pipecolic acid [
15N] α-aminoadipic acid
Derivatisation No Yes, FMOC-derivatisation
Detection mode Electrospray 
ionization, positive 
mode, MRM 
measurement
Electrospray ionization, 
negative mode, MRM 
measurement
Estimated batch (20 samples) 
sample preparation time
30 minutes 1 hour
LC-MS/MS single run time 7 minutes 14 minutes
Limit of quantification (S/N = 10) 0.02 mmol/mol cr. 0.05 mmol/mol cr.
Typical intra-assay CV’s < 10% < 10%
Typical inter-assay CV’s < 20% < 20%
Reference ranges *
0-6 months < 0.37 < 2
6-12 months < 0.1 < 1
> 12 months < 0.05 < 0.5
Pathological values (ranges)* $
0-6 months 0.6 - 19.4 12 - 76
6-12 months 1.5 - 18.9 2.5 - 101
> 12 months 0.2 - 8.6 0.6 - 5.8
Table I.  Description of the used P6C and α-AASA methodologies
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Discussion
The differential diagnosis in neonatal and infantile seizures includes PDS. Although 
relatively rare, with an estimated incidence up to 1:276 000 births in the Netherlands8, this 
condition is treatable and early diagnosis is of utmost importance. The current knowledge 
about the primary defect in PDS has provided new diagnostic biomarkers i.e. α-AASA and 
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Figure V.  P6C levels in patients with proven PDS using a logarithmic Y-axis presentation
Figure VI.  Relationship between α-AASA and P6C levels in urine samples from PDS 
patients; (Spearman correlation is 0.78; p < 0.001)
Boek_VB_bruin.indd   40 3-7-2013   20:50:14
41
P6C. Recent studies revealed that the clinical phenotype of PDS varies from classical PDS 
presenting as therapy resistant neonatal seizures to partly treatable seizures with the 
first presentation in early childhood9. The focus of our group, as well as others has been 
on the urinary levels of α-AASA, which can be detected by either LC-MS/MS or GC-MS, 
following a derivatisation procedure1,10. α-AASA is known to be in spontaneous equilibrium 
with its cyclic form P6C, however the mechanism of this equilibrium is poorly understood 
and therefore currently not inducible. Ongoing diagnostics and treatment monitoring with 
respect to PDS revealed that in individual cases the α-AASA increase was only modest 
compared to the appropriate reference range. These observations prompted us to focus 
on urinary P6C. P6C has previously been assessed in plasma of PDS patients and indeed, 
increases were detected11. We have chosen to investigate P6C levels in urine of patients 
as urinary samples can be obtained non-invasively, which is advantageous in subsequent 
therapy monitoring. Moreover, we have noticed that α-AASA has a strong tendency to bind 
with protein, and it can be expected that the same is true for P6C.
Our proposed LC-MS/MS method for the urinary P6C quantification shows sufficient 
sensitivity, is reproducible, and is relatively easy to perform. In an acute situation, results 
can be obtained within 15 minutes after urine sampling. The stability studies clearly 
revealed the importance of proper sample storage and shipment. The strong decline in P6C 
concentrations in Guthrie cards excludes this sampling procedure since there is a potential 
risk of false negative results. 
The observed positive correlation of both P6C and α-AASA and the protein intake by 
neonates pleads for a lysine restricted diet therapy, thereby lowering the flux through the 
lysine degradation pathway, resulting in lower levels of P6C and α-AASA. Currently, we are 
aware that such studies are underway, however no official results have been published. 
The diagnostic strength of urinary P6C and α-AASA assessments is comparable, implying 
that both markers can be applied in a diagnostic setting. In those cases where there is 
doubt about the identity of P6C or α-AASA, the alternative method can be used as a second 
tier test. The availability of P6C and α-AASA as biomarkers for PDS allows and encourages 
low-threshold screening for this treatable disorder, also in those cases where the clinical 
suspicion of PDS is low according to the classical criteria12. 
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Abstract
Recently, α-aminoadipic semialdehyde (α-AASA) dehydrogenase deficiency was shown to 
cause pyridoxine-dependent epilepsy (PDE) in a considerable number of patients. α-AASA 
dehydrogenase deficiency is an autosomal recessive disorder characterized by a neonatal-
onset epileptic encephalopathy in which seizures are resistant to antiepileptic drugs but 
respond immediately to the administration of pyridoxine (OMIM266100). Increased plasma 
and urinary levels of α-AASA are associated with pathogenic mutations in the α-AASA 
dehydrogenase (ALDH7A1/ antiquitin) gene. Here, we report an intriguing “silent” mutation 
in ALDH7A1, a novel missense mutation and a founder mutation in a Dutch cohort (10 
patients) with α-AASA dehydrogenase deficiency.
Chapter II.c
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Introduction
The first PDE patient was described more than 50 years ago1. However, it was not until 
recently that it was discovered that mutations in the α aminoadipic semialdehyde (α-AASA) 
dehydrogenase (ALDH7A1) gene cause PDE. Although patients respond immediately to 
the administration of pyridoxine, and often remain free of seizures during the lifelong 
treatment, most patients have developmental delay (OMIM266100). In all patients in whom 
pathogenic mutations were found, increased plasma and urinary levels of α-AASA were 
detected by Liquid Chromatography/mass spectrometry/mass spectrometry2. Currently, 
pathogenic mutations have been reported in 22 families, with a total of 24 mutations and 
29 patients2,3. 
We have sequenced the ALDH7A1 gene in a panel of 10 Dutch patients with biochemically 
proven α-AASA dehydrogenase deficiency (i.e. with increased α-AASA in body fluids). 
Subjects and Methods
Subjects
α-AASA dehydrogenase deficiency was biochemically confirmed (i.e. increased urinary and 
plasma α-AASA) for 10 patients from 7 unrelated families. These biochemical data and the 
clinical data has been published previously2,4,5 (Patient VI in Mills and colleagues study2 is 
Patient 8 in Been and coworkers4 and Bok and colleagues studies5). 
Methods 
DNA was isolated from blood of patients and their parents. The 18 exons, including the 
adjacent splice sites of ALDH7A1 were amplified by polymerase chain reaction (PCR) as 
previously described2. Subsequently, the purified PCR products were directly sequenced 
using an ABI PRISM® 3100 Genetic Analyzer (Applied Biosystems, CA, USA) and analyzed 
using Mutation Surveyor® (Softgenetics, PA, USA). In two cases, the ALDH7A1 gene was 
analyzed at the messenger RNA level. RNA was isolated from PAXgene Blood RNA Tubes 
(QIAGEN Netherlands QIAGEN Benelux B.V., Venlo, the Netherlands), complementary DNA 
was synthesised and subsequently the full-length open reading frame was amplified using 
TaKaRa LA Taq™ polymerase (Takara Bio Europe S.A.S., Saint-Germain-en-Laye France ) 
and primers 1F+18R (1F; AAAGACCAGCAAGCTCTCT, 18R; CTCCAAAAACAGCTGCTGGA). 
The primers were designed to amplify the ALDH7A1 mRNA only and not its pseudogene. 
These amplifications were directly sequenced. In addition, the amplicon harboring the 
homozygous mutation was cloned using the TOPO TA Cloning kit (Invitrogen, Paisly, United 
Kingdkom). Thirty-two individual clones were sequenced. 
Results
Pathogenic mutations were detected in all of the 10 patients from 7 apparently unrelated 
families with biochemically proven α-AASA dehydrogenase deficiency (Table I). In seven 
patients (four unrelated families; Patients 1,3,5,7,9,10, and 12, in the Bok and colleagues’ 
study5) the c.1195G > C; p.Glu399Gln mutation in exon 14 of ALDH7A1 was found to be 
homozygous; and in one patient (Patient 8), it was found to be heterozygous. 
An intriguing “silent” mutation and a founder effect in antiquitin (ALDH7A1)
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A novel homozygous ”silent” variant/mutation (c.750G > A) was detected in one of the 
patients (Patient 2). Her parents were carriers of this “silent” variant/mutation, confirming 
homozygosity in the affected child. The biochemically unaffected sibling (i.e. normal α-AASA 
levels) was heterozygous for the mutation like her parents. The mutation was not detected 
in 210 control chromosomes. The splice prediction tool of Berkely Drosophila Genome 
project (http://www.fruitfly.org/seq_tools/splice.html) suggested that in the wild-type 
sequence, 40 nucleotides upstream of the authentic donor site of IVS9, a cryptic donor site 
is located. The authentic donor site has an extremely high probability score of 0.99 (score 
varies from 0.1 - 1), but also the cryptic site has a reasonable score of 0.77 (Fig. I), which 
suggests that both sites may be used. The silent mutation is located within the cryptic site, 
resulting in an increase of its predicted score to 0.91. This does not affect the authentic 
An intriguing “silent” mutation and a founder effect in antiquitin (ALDH7A1)
gDNA sequence analysis of 3’ end of exon 9 and the donor sequence of IVS9 of the ALDH7A1 gene. A) 
The cryptic donor site (TCAGIGTGGA) and the authentic donor site (TTTGIGTAAGT), including the probability 
scores (0.77 and 0.99, respectively) in the wildtype sequence are depicted. B) In DNA of the parent both 
the wildtype allele as well as the allele containing the c.750G > A (N = G/C) mutation are detected (arrow), 
resulting in two probability scores for the cryptic upstream donor site (0.77 and 0.91). C) In DNA of the patient 
only the homozygous transition (c.750G > A) is present, resulting in the increase of the probability score to 
0.91 for the cryptic donor site (TCAGIGTGGG; 0.91), but without a predicted effect on the authentic donor 
site 40 nt upstream. Correct splicing (D) and erroneous splicing (E) of ALDH7A1 mRNA isolated from blood 
of control and patient, respectively. In the control, only mRNA spliced at the authentic donor site is detected. 
No difference between this control RT-PCR and that of the parents was seen, indicating that mRNA spliced at 
the upstream donor site probably results in instable mRNA. The arrow indicates the position of the nucleotide 
involved in the mutation (see A-D).
Figure I. The c.750G > A mutation results in erroneous splicing and unstable 
ALDH7A1 mRNA
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HS  1   ----------------------------MSTLLINQPQYAWLKELGLR-EENEGVYNGSWGGRGEVITTYCPANNEPIARVRQASVADYEETVKKAREAWKIWADIPAPK
PT  1   MWRLPRALCVHAAKTSKLPGPWSRPAAFMSTLLINQPQYAWLKELGLR-EENEGVYNGSWGGRGEVITTYCPANNEPIARVRQASVADYEETVKKAREAWKIWADIPAPK
BT  1   ----------------------------MSTLLINQPQYAWLKELGLR-EENDGVYNGSWGGRGEVITTYCPANNEPIARVRQASMADYEETVEKAREAWSIWADVPAPK
RN  1   MLRLARPLCVQTVKASKLSRLWSRPAALMSTLLIHHPQYAWLQDLGLR-EDNEGVFNGSWGGRGEVITTYCPANNEPIARVRQASMKDYEETIGKAKKAWNIWADIPAPK
MM  1   ----------------------------MSTLLIHHPQYAWLQDLGLR-EDNEGVYNGSWGGRGEVITTYCPANNEPIARVRQASLKDYEETIGKAKKAWNIWADIPAPK
GG  1   MLGWRRAAASVLLLPRRAG---WRPAAAMSSLLVGQPQYAWLRELGLQ-EDNPGVYNGRWGGGGQVVTTYCPANNEPIARVRQASLEDYEETVKKAKEAWQVWADIPAPK
DR  1   ----------------------------MSTLLINQPEYNWLKELGLK-EDNDGVYNGSWGGQGEVVTSYCPANNEPIARVRQATIAEYEETIQKALDAWKVWADVPAPK
AS  1   ----------------------------MSGLLINQPKYSWLKELGLS-EDNPGVYNGSWGGSGEVITSYCPANNEPIARVTQATLAEYEETVQKTREAWKMWADIPAPK
XT  1   ----------------------------MSSLLINQPEYSWLKELGLK-EDNEGVYNGTWGGKGEVVTSYCPGNNAPIARVKQATLDEYNETVNKAKEAWKIWADIPAPK
CE  1   ----------MNRLLSSGMSAATLQTRMASQLLINDSKYGFLKELGLT-ENNAGVFHGKWAASGQVVQSFAPANNSPIANVQNGNVQDYEIAISEAKKAYNDWCEVPAPR
DM  1   --MLAQLRNISKLALPRRLVTQTASYSSSSSYLIDQPEYSFLKELGLE-RDNPGVYSGQWQGRGPSVTSYDPGTGQPIAKVRQGNVQELEHTIGLAVEAYKQWRQVPAPV
MD  1   -------------------------------MGFAKKEHEFLSAIGLAPENPGGFINGKWKASGPVISTVSPSNNQEIAKVTEVSMEEYEEGLRSCNDAAKTWKSLPAPK
DD  1   --------------------------------MTTFNEYPFLAELGIKAENNDGVFNGKWGGAGEIIKCLNPTNNKVIATVRGAAPEEYETCIQAMLAAKVKWALTPAPR
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
HS  82  RGEIVRQIGDALREKIQVLGSLVSLEMGKILVEGVGEVQEYVDICDYAVGLSRMIGGPILPSERSGHALIEQWNPVGLVGIITAFNFPVAVYGWNNAIAMICGNVCLWKG
PT  110 RGEIVRQIGDALREKIQVLGSLVSLEMGKILVEGVGEVQEYVDICDYAVGLSRMIGGPILPSERSGHALIEQWNPIGLVGIITAFNFPVAVYGWNNAIAMICGNVCLWKG
BT  82  RGEVVRQIGDALREKIQVLGSLVSLEMGKILVEGVGEVQEYVDVCDYAVGLSRMIGGPILPSERPGHALIEQWNPVGLVGIITAFNFPVAVYGWNNAIAMICGNACLWKG
RN  110 RGEIVRKIGDALREKIQLLGRLVSLEMGKILVEGIGEVQEYVDVCDYAAGLSRMIGGPTLPSERPGHALMEQWNPLGLVGIITAFNFPVAVFGWNNAIALITGNVCLWKG
MM  82  RGEIVRKIGDAFREKIQLLGRLVSLEMGKILVEGIGEVQEYVDVCDYAAGLSRMMGGPTLPSERPGHALIEMWNPLGLVGIITAFNFPVAVFGWNNAIALITGNVCLWKG
GG  107 RGEVVRQIGDALRQKIKVLGSLVSLEMGKIYVEGVGEVQEYVDVCDYAVGLSRMIGGPVLPSERSGHALIEQWNPVGLVGIITAFNFPVAVYGWNSAIAMICGNACLWKG
DR  82  RGEIVRQIGEALRRKIKALGSLMSLEMGKVYVEGVGEVQEYVDVCDYAVGLSRMIGGPILPSERPGHVLIEQWNPVGLVGIITAFNFPVAVYGWNNAIALICGNACLWKG
AS  82  RGEIVRQIGDALRKKIKVLGSLVSLEMGKIYVEGVGEVQEYVDVCDYAVGLSRMIGGPVLPSERPGHALIEQWNPVGLVGIITAFNFPVAVYGWNNAIALTCGNVCLWKG
XT  82  RGEIVRQIGDALRKKIKLLGHLESLEMGKILVEGVGEVQEYVDICDYAVGLSRIIGGPILPSERPGHALIEQWNPVGLVGIITAFNFPVAVYGWNNALALICGNVCLWKG
CE  100 RGEIVRQIGDKLRTQLQNLGKLVSLEMGKISAEGVGEVQEYVDICDYATGLSRSLEGKIFPSERPGHALLEQWNPLGVVGVISAFNFPCAVYGWNNALALVTGNSVVWKP
DM  108 RGEIVRQIGDELRKYKEPLGKLVSLEVGKIYSEGQGEVQEFIDICDYAVGLSRIYSGQLINSERADHSILEAWRPLGVVGVISAYNFPNAVFGWNAAIALTTGNSVLWKG
MD  80  RGEIVRQIGDALREKLQHLGKLVSLEMGKILAEGIGEVQEVIYMCDFAVGLSRQLNGSIIPSERPDHMMFEVWNPLGIVGVITAFNFPCAVLGWNACIALVCGNCVVWKG
DD  79  RGEIVRLIGQAMREKIEPLSKLISLEMGKIYIEAKGEVQEFIDVCDYATGLSRSINGQVMPSERPNHILMETWNPLGLVGIITAFNFPCAVLGWNAAISMICGNVQLWKG
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
HS  192 APTTSLISVAVTKIIAKVLEDNKLPGAICSLTCG-GADIGTAMAKDERVNLLSFTGSTQVGKQVGLMVQERFGRSLLELGGNNAIIAFEDADLSLVVPSALFAAVGTAGQ
PT  220 APTTSLISVAVTKIIAKVLEDNKLPGAICSLTCG-GADIGTAMAKDERVNLLSFTGSTQVGKQVGLMVQERFGRSLLELGGNNAIIAFEDADLSLVVPSALFAAVGTAGQ
BT  192 APTTSLISVAVTKIIAKVLEDNKLPGAICSLTCG-GADIGTAMAKDERVDLLSFTGSTQVGKQVALMVQERFGRSLLELGGNNAIIAFEDADLSLVVPSALFAAVGTAGQ
RN  220 APTTSLVSIAVTKIIAKVLEDNLLPGAICSLTCG-GADMGTAMARDERVNLLSFTGSTQVGKQVALMVQERFGKSLLELGGNNAIIAFEDADLSLVLPSALFAAVGTAGQ
MM  192 APTTSLVSVAVTKIIAQVLEDNLLPGAICSLVCG-GADIGTTMARDERVNLLSFTGSTQVGKEVALMVQERFGKSLLELGGNNAIIAFEDADLSLVVPSVLFAAVGTAGQ
GG  217 APTTSLTSVAVTKIVAKVLEDNKIPGAVCSLVCG-GADIGTAMARDERMDLLSFTGSTEVGKQVALMVQERFGRSLLELGGNNAIIVFEDADLNLVIPSTLFAAVGTAGQ
DR  192 APTTPLTSVAVTKIVAEVLEQNHLPGAICSMTCG-GADIGMAMAKDERVGLLSFTGSTHVGKQVAMMVQERFGRQLLELGGNNAIIVFEDADLSLVVPSAVFASVGTAGQ
AS  192 APTTPLTSVAVTKIVAEVLEQNNLPGAICSMTCG-GADIGTAMAKDERVDLLSFTGSTHVGKMVAMMVQERFGRKLLELGGNNAIIVFEDADLNLVVPSAVFASVGTAGQ
XT  192 APTTSLTSVAVTKIVAQVFEDNKLPGAICSLTCG-GADIGNAIAKDERVDLVSFTGSTNVGKQVALKVQERFGRKLLELGGNNAIIVFEDADLSLVTPSVLFAAVGTAGQ
CE  210 APSTPLTAIAVTKLVEEVLVANNVNPALCSLVCG-EGDVGQALVKDKRVNLVSFTGSSEIGKIVGQQVQARFGKLLLELGGNNAIIVNEDADLNMVVPATVFAAVGTAGQ
DM  218 APSTPLVSVATTKIVAEVLRRNNLP-PVVTLCQG-GTDVGQTLVADKRVNLVSFTGSCQTGRDVGVEVQRRFGKVILELGGNNALIIDESANVKMALDAALFGCIGTSGQ
MD  190 APTTPLVTIAVTKLIAEVLEKNNLPAAIFTAFCG-GAEIGEAIAKDTRIPLVSFTGSSKVGAKVQQIVTERFGKCLLELSGNNALIVMDDADVGLAVRSIFFAAVGTAGQ
DD  189 ASTTSLITLAVSKIIEKVLVENDVDPAVCCVLIGPGRTVGEQMIQDKRFGLISFTGSTEVGRRISSTVHGYFGKTILELGGNNAIVVAEDADIELVLRAVLFASVGTTGQ
       
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|...|....| 
HS  301 RCTTARRLFIHESIHDEVVNRLKKAYAQIR--VGNPWDPNVLYGPLHTKQAVSMFLGAVEEAKKEGGTVVYGGKVMD-RPGNYVEPTIVTGLGHDASIAHTETFAPILYV
PT  329 RCTTVRRLFIHESIHDEVVNRLKKAYAQIR--VGNPWDPNVLYGPLHTKQAVSMFLGAVEEAKKEGGTVVYGGKVMD-RPGNYVEPTIVTGLGHDASIAHTETFAPILYV
BT  301 RCTTARRLFLHESIHDEVVNRLKKAYAQIR--VGNPWDSNVLYGPLHTKQAVSMFLGAVEEAKKEGGTVVYGGKVMD-RPGNYVEPTIVTGLDHDASIVHTETFAPILYV
RN  329 RCTTVRRLFLHESIHDEVVDRLKNAYSQIR--VGNPWDPNILYGPLHTKQAVSMFVQAVEEAKKEGGTVVYGGKVMD-HPGNYVEPTIVTGLVHDAPIVHKETFAPILYV
MM  301 RCTTVRRLFLHESIHNEVVDRLRSAYSQIR--VGNPWDPNILYGPLHTKQAVSMFVRAVEEAKKQGGTVVYGGKVMD-HPGNYVEPTIVTGLAHDAPIVHQETFAPILYV
GG  326 RCTTARRLFLHENIHDEVVEKLVKAYAQVR--IGDPWDSDTLYGPLHTKAAVKMFLDAVEQAKQQGGSVVYGGKVIN-RPGNYVEPTIVTGLAHNAPIVHTETFAPILYV
DR  301 RCTTTRRLMLHESIHDEVVERIAKAYKQIR--IGDPWDPNTLYGPLHTKQAVQQYLAAIEQAKQQGGTLVCGGKIMD-RPGNYVEPTIITGLPHNASIVHTETFVPILYV
AS  301 RCTTTRRLMLHESVHDAVVERIAKAYKQVR--IGDPWDPSTLYGPLHTKQAVDQYLAAIEQAKQQGGTLVCGGKVMD-RPGNYVEPTIITGLAHDAPIVHTETFVPILYV
XT  301 RCTTARRLFLHESIHDEIVEKLSKAYAQVR--IGDPCAPDTLCGPLHTKQAVEMYLSAVEQAKCEGGTVVCGGKVID-RPGNFVEPTIMTGLAHDAAIVHKETFAPILYV
CE  319 RCTTTRRLIVHDKVYDQVLERLKKAYAQFESRIGCPLDSNTIIGPLHNQQAVGKYKASVAEAVASGGKIEYGGKVLE-RDGNFVLPTIVTGLKHDSPVVLRETFAPILYV
DM  326 RCTTTRRIIVHEKLHDQFVKELVGKYKQLISKIGHQLEAQTLVGPVHTQQNVENYKAAIAEAKSLGGTVAFGGNVIQ-RDGFYVEPTVITGLPHDASVVHRETFAPIVYI
MD  299 RCTTCRRLYLHESIYQNVLDKLVGLYNQVK--IGDPLEEGTLVGPVHTKASRENFEKGISTIKSQGGKILTGGSVIE-SDGNFVQPTIVE-IASNASVVKEELFGPVLYV
DD  299 RCTTCRRLFVHESLYDTILERLTKAYKTIK--IGNPLEEGVLVGPLHTQSAVKEFTEGLEEIKKQGGKVVIGGNKLDISGGNFVEPTVVA-IEHDAPIVKTELFVPILYI
Glu399Gln
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|. 
HS  408 FKFKNEEEVFAWNNEVKQGLSSSIFTKDLGRIFRWLGPKGSDCGIVNVNIPTSGAEIGGAFGGEKHTGGGRESGSDAWKQYMRRSTCTINYSKDLPLAQGIKFQ--  
PT  436 FKFKNEEEVFAWNNEVKQGLSSSIFTKDLGRIFRWLGPKGSDCGIVNVNIPTSGAEIGGAFGGEKHTGGGRESGSDAWKQYMRRSTCTINYSKDLPLAQGIKFQ--  
BT  408 FKFKNEDEVFAWNNEVKQGLSSSIFTKDMGRIFRWLGPKGSDCGIVNVNIPTSGAEIGGAFGGEKHTGGGRESGSDAWKQYMRRSTCTINYSKDLPLAQGIKFQ--  
RN  436 FKFKNEEEVFEWNNEVKQGLSSSIFTKDLGRIFRWLGPKGSDCGIVNVNIPTSGAEIGGAFGGEKHTGGGRESGSDAWKQYMRRSTCTINYSTALPLAQGIKFQ--  
MM  408 FKFQDEEEVFEWNNEVKQGLSSSIFTKDLGRIFRWLGPKGSDCGIVNVNIPTSGAEIGGAFGGEKHTGGGRESGSDAWKQYMRRSTCTINYSTSLPLAQGIKFQ--  
GG  433 LKFKEEEEVFAWNNEVKQGLSSSIFTRDLGRIFRWLGPKGSDCGIVNVNIPTSGAEIGGAFGGEKHTGGGRESGSDSWKLYMKRSTCTINYSKDLPLAQGIKFQ--  
DR  408 LKFKTEEEAFSWNNEVKQGLSSSIFTKDMGRVFRWLGPKGSDCGIVNVNIPTSGAEIGGAFGGEKHTGGGRESGSDSWKQYMRRSTCTINYSKDLPLAQGIKFE--  
AS  408 LKFKTEEEAFAWNNEVQQGLSSSIFTKDLGRVFRWLGPKGSDCGIVNVNIPTSGAEIGGAFGGEKHTGGGRESGSDSWKQYMRRSTCTINYSKDLPLAQGIKFE--  
XT  408 IKFKTEEEAFAWNNEVKQGLSSSIFTKDLGRIFRWLGPKGSDCGLVNVNIPTSGAEIGGAFGGEKHTGGGRESGSDSWKHYMRRSTCTINYSKDLPLAQGIKFQ--  
CE  428 LKFSTLEEAIAINNEVDQGLSSSLFTTNIQNVFKWMGPKGSDCGIVNVNIPTSGAEIGGAFGGEKETGGGRESGSDSWRQYMRRSTCTINYSKELPLAQGIKFE--  
DM  435 LKAKNVDQAIEWNNEVEQGLSSAIFTENIGQAFKWIGAKGSDCGIVNINTTTNGAEIGGAFGGEKATGGGRESGSDAWKQYCKRATITVNHSGELACAQGVVFNVE  
MD  405 MKFKTLEEAIALNNSVPQGLSSSIFTSKPNTIFKWIGPHGSDCGIVNVNIPTNGAEIGGAFGGEKATGGGREAGSDSWKQYMRRSTCTINYGTELPLAQGINFG--  
DD  406 MKFKNLDDAFAWNNEVPQGLSSSLFTNNQKNIFKWLGPTGSDCGIVNVNVATNGAEIGGAFGGEKETGGGRESGSDSWKQYCRRSTNTINYGNTMPLSQGINFN--  
Cys450Ser
2 12 21 31 41 51 61 71 81
91 101 111 121 131 141 151 161 171 181 191
101 201 221 230 240 250 260 270 280 290 300
310 320 330 338 348 358 368 377 387 397 407
417 427 437 447 457 467 477 487 497 507 
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Alignment was determined by the ClustalW BioEdit, CA USA program using the ALDH7A1 proteins that were 
identified to be most related to the homo sapiens ALDH7A1 protein by the blastp search. The boxshade 
program was used to visualize identical amino acids (highlighted in black) and functionally conserved amino 
acids (in grey). The arrows point at the two amino acids involved in the missense mutations detected in the 
present study. Functionally conserved amino acids are classified as follows: V, I, L, and M; D, E, Q, and N; F,Y, 
and W; G, S, T, P, and A; and K, R, and H. HS Homo sapiens GI 4557343, PT Pan troglodytes GI 114601421, 
BT Bos Taurus GI 114051810, RN Rattus norvegicus GI 62664437, MM Mus musculus GI 74219152, GG Gallus 
gallus GI 118104602, DR Danio rerio GI 47086597, AS Acanthopagrus schlegeli GI 61742178, XT Xenopus 
tropicalis GI 62858515, CE Caenorhabditis elegans GI 115534176, DM Drosophila melanogaster GI 24666674, 
MD Malus x domestica GI 25090068, DD Dictyostelium discoideum GI 66818493.
Figure II.  Box alignment of ALDH7 proteins
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donor site. Similar results were obtained when other splice prediction tools were used 
(e.g. www.genet.sickkids.on.ca/~ali/splicesitefinder.html). RNA isolated from the blood of 
patient, parents and controls followed by RT-PCR and sequencing of the cDNA demonstrated 
that only the authentic site appears to be used in the control. However, analysis of the RNA 
from our patient, who is homozygous for the c.750G > A variant, demonstrated that the 
cryptic site is preferentially used over this authentic site. In contrast, RNA isolated from 
blood of the parents, who are heterozygous for the mutation, showed only the presence of 
properly spliced mRNA. This suggests that the eroneous splicing results in mRNA that could 
be subjected to non-sensense-mediated decay6, resulting in the abundance of authentic 
spliced transcripts over the aberrant spliced transcripts. The low abundant aberrant mRNA 
is the only form present in the index, allowing this to be amplified by PCR in contrast 
with the heterozygotes where the high abundane of authentic spliced transcripts probably 
interferes. The cloning of the amplicons showed that 29 of 32 clones that could be analyzed 
had a deletion of the last 40 nucleotides of exon 9 (r.748_787del), arising from the cryptic 
donor site (c.749) decribed earlier. This predicts a framshift leading to a new stop codon 
23 amino acids downstream of the valine (p.Val250GlyfsX23). The three remaning clones 
harbored the authentic spliced sequence, indicating that normal splicing also occurs at a 
lower rate.
In DNA of Patient 4, the heterozygous splice mutation described earlier (c.750G > A) and 
a novel heterozygous missense variant were detected. Sequence analysis of the complete 
open reading frame at the complementary DNA level showed only the presence of a properly 
spliced allele containing the novel missense variant (c.1348T > A; p.Cys450Ser). The 
cysteine residue as well as the protein region is highly conserved in evolution (Fig. II). The 
missense variant was not detected in 210 control chromosomes. Compound heterozygosity 
for both alleles was only detected in the affected sibling and not in the two unaffected 
siblings and/or the parents.
Discussion
The c.1195G > C; p.Glu399Gln mutation was detected in the majority of the Dutch α-AASA 
dehydrogenase (antiquitin) alleles. It has been reported that this mutation occurs in 13 
out of 48 alleles (24 index patients) showing that this mutation has a high frequency2,3 
(Table I). The fact that this mutation was detected in 9 out of 14 alleles from apparently 
unrelated Dutch index patients (including a previously described Dutch allele2) is a strong 
argument for a founder effect.
In two Dutch families, a novel “silent” mutation (c.750G > A) was found, a type of DNA 
variation that is often considered to be nonpathogenic because the coding sequence 
and/or protein function is thought to be altered. Interestingly, this variant proved to be the 
pathogenic mutation, because it results in erroneous splicing (Fig. I). This is in agreement 
with the absence of the mutation in control chromosomes, the data obtained with the 
free web-based splice prediction tools, and the segregation of the homozygous mutation 
with the clinical phenotype within the family. Although highly speculative, it is of note, 
that in the patient who is homozygous for this “silent” mutation, both urinary and plasma 
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AASA levels (4.0 mmol/mol creatinine and 1.1 umol/L, respectively), although increased 
compared to controls, appear to be moderately increased compared to those found in 
other Dutch patients (n = 10: range 9.6 - 75 mmol/mol creatinine, and 0.8 - 8.0 umol/L, 
respectively). This may suggest the presence of very low levels of properly spliced mRNA, 
which would be expected based on the presence of the unaffected authentic splice site and 
was confirmed by the fact that 3 of 32 (approximatly 9%) clones contained the authentic 
spliced mRNA. 
Furthermore, this mutation has also been detected in another patient. This “silent” mutation 
(c.750G > A, heterozygous) described above, was found in conjunction with a novel 
heterozygous missense mutation that results in the replacement of a cysteine by a serine 
(p.Cys450Ser). The latter is considered pathogenic based on the following 4 arguments: 
(1) the cysteine residue and the protein region are highly conserved throughout evolution 
(Fig. II); (2) the missense mutation was not detected in 210 control chromosomes; (3) 
compound heterozygosity for both alleles was detected only in the affected sibling and not 
in the 2 unaffected siblings and both parents; and (4) no additional mutations or splice 
aberrations were detected in the mRNA, making it unlikely that another mutation had been 
missed. It is notable that also in this patient, the increase of α-AASA levels (urine 4.7 mmol/
mol creatinine, plasma 0.9 umol/L) is modest compared to other α-AASA dehydrogenase 
deficient patients (n = 10: range; urine 9.6 - 75 mmol/mol creatinine, plasma: 0.8 - 8.0 
umol/L). However, the limited number of patients tested does not allow any definitive 
conclusion on these metabolite levels, and further enzyme studies are warranted. 
The study further emphasizes that elevated urinary α-AASA is associated with pathogenic 
mutations in ALDH7A1. This illustrates that increased α-AASA levels should be used as a 
non-invasive pathognomonic marker in diagnostic laboratories. It may be desirable, at least 
in the Netherlands, but likely in a broader area, first to analyze the DNAs for the presence 
of mutations in exons 14 (p.Gln399Glu), 9 (c.750G > A) and 4 (p.Arg82X) of ALDH7A1, 
before sequencing the complete open reading frame (i.e. an additional 15 exons). 
Furthermore, we detected an intriguing “silent” mutation that led to the introduction of a 
cryptic splice site that predicts to encode a truncated protein. Notably, a silent variant may 
also have an effect on cis-elements, resulting in erroneous splicing6, or it may even lead 
to different kinetics of mRNA (protein) translation7. This study illustrates the importance 
of mRNA studies when a seemingly nondisease-causing variant is detected or in the case 
where there is a strong suspicion of α-AASA dehydrogenase deficiency (i.e. increased 
urinary levels of α-AASA) without the identification of one or both mutated ALDH7A1 
alleles. The fact that ALDH7A1 is expressed in blood allows the inclusion of mRNA studies 
in such occasions. 
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Abstract 
Purpose: Pyridoxine Dependent Epilepsy (PDE) is characterized by therapy resistant 
seizures (TRS) responding to intravenous (IV) pyridoxine. PDE can be identified by increased 
urinary α-AASA concentrations and mutations in the ALDH7A1 (antiquitin) gene. Prompt 
recognition of PDE is important for treatment and prognosis of seizures. We aimed to 
determine whether immediate electroencephalography (EEG) alterations by pyridoxine-IV 
can identify PDE in neonates with TRS.
Methods: In 10 neonates with TRS, we compared online EEG alterations by pyridoxine-IV 
between PDE (n = 6) and non-PDE (n = 4). EEG segments were visually and digitally analyzed 
for average background amplitude and total power and relative power (background activity 
magnitude per frequency band and contribution of the frequency band to the spectrum).
Results: In 3 of 10 neonates with TRS (2 of 6 PDE and 1 of 4 non-PDE neonates), 
pyridoxine-IV caused flattening of the EEG amplitude and attenuation of epileptic activity. 
Quantitative EEG alterations by pyridoxine-IV consisted of (1) decreased central amplitude, 
p < 0.05 [PDE: median -30% (range -78 to -3%); non-PDE: -20% (range -45 to -12%)]; 
(2) unaltered relative power; (3) decreased total power, p < 0.05 [PDE: -31% (-77 to 
-1%); -27% (-73 to -13%); -35 % (-56 to -8%) and non-PDE: -16% (-43 to -5%); 
-28% (-29 to -17%); -26% (-54 to -8%), in delta-, theta- and beta-frequency bands, 
respectively]; and (4) similar EEG responses in PDE and non-PDE.
Discussion: In neonates with TRS, pyridoxine-IV induces non-specific EEG responses 
that neither identify nor exclude PDE. These data suggest that neonates with TRS should 
receive pyridoxine until PDE is fully excluded by metabolic and/or DNA analysis.
Keywords: Neonatal seizures, Electroencephalography, Antiquitin, ALDH7A1 gene 
mutations, Pyridoxine. 
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Introduction
For accurate treatment of neonatal seizures, it is important to first ascertain underlying 
etiology1. Under some conditions (such as pyridoxine dependent epilepsy (PDE), 
pyridoxine 5’-phosphate oxidase deficiency (PNPO) and folinic acid responsive seizures), 
therapy resistant seizures (TRS) may respond to administration of pyridoxine (vitamin B6) 
and/or pyridoxal phosphate2-5. The incidence of PDE is relatively low (1:300 000 newborns 
in the Netherlands6). Classical presentations of PDE concern early, intractable neonatal 
seizures that cease after pyridoxine administration7,8. PDE is caused by an inherited 
metabolic disorder of lysine degradation, resulting in increased urinary alpha-aminoadipic 
semialdehyde (α-AASA) excretion. In addition to increased urinary α-AASA concentrations, 
mutations in the ALDH7A1 (antiquitin) gene can also identify PDE9-14. Although prognosis 
may vary even after early treatment15, it is conceptualized that fast and accurate PDE 
treatment could be beneficial16-19. 
To avoid delay by biochemical and genetic testing, diagnostic trajectories often 
include an empirical pyridoxine trial. Such pyridoxine trials generally involve 
assessment of the clinical response to pyridoxine administration and subsequent 
withdrawal20-22. In TRS patients, there are two common routes for pyridoxine 
administration: (1) The intravenous (IV) route, which is generally associated with fast 
clinical and EEG responses, and (2) the oral route, which is generally associated with 
slower clinical and EEG responses17,20. In perspective of the faster response, the 
IV-route is often applied in neonates with a high seizure frequency. 
Prior to pyridoxine-IV, neonatal EEG signals have been characterized by a discontinuous 
background activity23-25, with bilateral high-voltage delta waves and with central/
temporal (poly)spikes24. After pyridoxine-IV, epileptic activity may disappear 
instantaneously26,27. This effect can be accompanied by other EEG characteristics, 
such as flattening of the EEG trace23,24,28. However, pyridoxine-IV EEG responses can 
vary among PDE patients25, and the specificity of EEG signals can be affected by many 
different anti-epileptic drug (AED) treatments that children with PDE often receive prior to 
pyridoxine-IV23,29. In addition, one should also take into account that EEG signals in PDE 
neonates would be expected to differ from EEG signals in older children with PDE8. Finally, it 
is indicated that pyridoxine-IV may also induce a favourable anti-epileptic effect in absence 
of PDE30. Accordingly, we have shown that pyridoxine-IV can nonspecifically reduce the 
EEG amplitude in non-PDE neonates with TRS31, we therefore reasoned that non-specific 
EEG effects could hamper the clinical interpretation of the pyridoxine-IV trial. 
Given the preceding, we aimed to investigate whether direct EEG responses to pyridoxine-
IV allow prompt identification of neonatal PDE. For this purpose, we compared quantitative 
(digital) and qualitative (visual) EEG responses to pyridoxine-IV between neonates 
characterized by PDE (by ALDH7A1 gene mutation) and neonates characterized by non-
PDE. To the best of our knowledge, such quantitative EEG responses to pyridoxine-IV have 
not been systemically investigated before in a homogeneous neonatal PDE cohort. 
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Patients
In TRS (PDE and non-PDE) neonates, we retrospectively collected and compared EEG 
recordings during first pyridoxine-IV exposure. The medical ethical committee of the 
University Hospital Groningen approved the present study. TRS were defined as seizures 
that do not respond to adequate administration of at least two first-line AEDs. Prescibed AED 
prior to the pyridoxine-IV administration involved therapeutic dosages of benzodiazepines, 
phenytoin, lidocaine and/or phenobarbital (Table I). PDE was defined according to the 
clinical criteria of Baxter22 and confirmed by ALDH7A1 gene mutation analysis9,13. All 
PDE data were derived from the Dutch study cohort (until January 2010 consisting of 
a total of 15 PDE children; see for further description Bok et al.9). For analysis of PDE 
data, we selected all six neonatal (< 3 months of age) EEG recordings that were obtained 
during first pyridoxine-IV exposure. All six PDE neonates were born, treated, and recorded 
between 1999 and 2008, at five different academic hospitals in the Netherlands (Academic 
Medical Center Amsterdam; Erasmus Medical Center Rotterdam; University Medical Center 
Groningen; University Medical Center Nijmegen; University Medical Center Utrecht). After 
parental informed consent (2008), we retrospectively performed EEG analysis in PDE 
neonates at the University Medical Center Groningen (between 2008 and 2009). Except 
for PDE neonate 6, all other (n = 5) included PDE neonates were homozygous for the 
common Dutch- c.1195G > C mutation in ALDH7A1. PDE neonate 6 appeared compound 
heterozygous with a c.1195G > C mutation and a c.244C > T mutation13. In all PDE neonates, 
urine α-AASA levels were increased (≥ 9 mmol/mol creatinine; controls < 1 mmol/mol 
creatinine), whereas in all non-PDE neonates urine α-AASA levels were normal. 
All non-PDE neonates were born, treated, and recorded between 2001 and 2004 at the 
University Medical Center Groningen [see for patient characteristics31]. After parental 
informed consent (obtained in 2005), we retrospectively performed non-PDE EEG analysis 
at the University Medical Center Groningen31. One of the analyzed pyridoxine responsive 
TRS neonates (former case 3) was definitely diagnosed with PDE and was, therefore 
assigned to the present PDE group. We consecutively obtained pyridoxine-IV EEG data for 
four remaining non-PDE neonates [< 3 months of age; i.e., former cases 1, 2 5, and 631]. 
The above described patient selection criteria resulted in relatively homogeneous PDE and 
non-PDE characteristics, both regarding seizure onset (0 - 2 days after birth) and regarding 
the timing of EEG recordings (2 - 15 days after birth). Patient data are shown in table I. 
Methods
In all 10 included neonates with TRS, we visually analyzed EEG recordings during the first 
pyridoxine-IV administration. All TRS neonates received 100 mg pyridoxine-IV, except for 
one PDE neonate and one non-PDE neonate who received 50 and 300 mg, respectively. 
Both 5 - 15 minutes before and after pyridoxine-IV, we obtained two one-minute EEG 
segments involving identical vigilance states. Segments were excluded for artifacts. All 
EEGs of TRS neonates were subsequently assigned and compared between PDE and non-
PDE subgroups. 
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Visual EEG analysis
We visually compared the EEG response during pyridoxine-IV between neonatal PDE and 
non-PDE (six and four neonates, respectively). EEG recordings of PDE neonates consisted 
of four digital 21-channel registrations, one digital amplitude integrated EEG (aEEG) 
registration and one paper 21-channel registration. EEG recordings in non-PDE neonates 
consisted of four digital 21-channel EEG registrations.
Quantitative analysis of digital EEG recording 
We assessed the same EEG segments for both digital and visual analysis. In eight TRS 
neonates, we digitally analyzed eight EEG recordings for amplitude, total and relative 
power (in delta, theta and beta frequency-bands). Quantitative EEG data of TRS neonates 
were subsequently subdivided and compared between PDE (n = 4) and non-PDE (n = 4) 
subgroups. 
Total power reflects the magnitude of background activity for an individual frequency 
band. Relative power indicates the relative contribution of a frequency-band to the 
entire spectrum32. Digital EEGs were analyzed by Brainlab (version 4.00-0.00) and 
Brain Vision Analyzer (version 1.030002). Bipolar recordings were evaluated at frontal 
(F3-F4), centro-temporal (T3-C3;C4-T4), central (C3-C4) and occipital (O1-O2) electrodes. 
The mean amplitude was calculated for each segment of 60 seconds (sampled at 256 
Hz), after rectification. For power calculations, we applied a Fast Fourier Transform 
algorithm, as implemented in Brain Vision Analyzer, employing a 10% Hanning window 
and using segments of 60 s, resulting in a spectral resolution of 0.016 Hz. Before and after 
Infant Signal AED at  pyridoxine-IV
Seizure  
classifica-
tion
Seizure  
type
Seizure 
onset
Age  
Pyrid-IV
Urine 
conc. 
AASA
PDE 1 D B, PB G Myoglonic 0 d 3 d 9.6
2 D B, LD MF Miscelaneous 0 d 3 d 71
3 D B, PB, P G Tonic 0 d 15 d 32
4 D PB, P G Myoclonic 0 d 2 d 24
5 aEEG B, PB, LD MF Miscelaneous 2 d 7 d 32
6 P B, PB, P MF Toni Clonic 0 d 3 d 12
Non-PDE 1 D B, PB C, G Toni clonic 0 d 12 d < 1
2 D B, PB, LD S, G Subtle 0 d 2 d < 1
3 D B, PB S, G Toni Clonic 1 d 7 d < 1
4 D B, LD, PB S, G Tonic clonic 1 d 13 d < 1
Table I.  Clinical data of neonates with therapy-resistant seizures (TRS)
PDE, pyridoxine dependent epilepsy; AED, antiepileptic drug; IV, intravenous; conc., concentration; AASA, 
alpha-aminoadipic semialdehyde in mmol/mol creatinine (normal value < 1); D, digital; aEEG, amplitude 
integrated EEG; B, benzodiazepines; P, phenytoin; LD, lidocaine; PB, phenobarbital; C, cryptogenic; S, 
symptomatic; G, generalized; MF, multifocal; d, postnatal day(s). 
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pyridoxine-IV, we compared relative power in each frequency-band. Relative power 
calculation was performed according to the formula (Prelative [f1, f2] = P[f1, f2] / P[0.50] x 
100%)31, where P[f1, f2] is the total power in the frequency-band between f1 and f2 Hz.32. 
Statistical analysis
Before and after pyridoxine-IV, we applied Wilcoxon signed rank test to assess EEG 
alterations (for amplitude, total- and relative- power). We applied Mann-Whitney U-test 
to compare quantitative EEG alterations (regarding amplitude, total- and relative- power) 
between PDE and non-PDE subgroups. We stratified results for vigilance state (i.e. sleeping 
or waking) by Mann-Whitney U-test. The level of significance was set by α = 0.05. 
Results
Visual EEG assessment
We observed a flattening of the EEG response (i.e. iso-electrical trace) and attenuation of 
epileptic activity in two of six neonatal PDE trials and in one of four non-PDE trials. Both 
15 minutes before and after pyridoxine-IV, visual assessment did not reveal diagnostic 
EEG features that can identify PDE or non-PDE in a sensitive or specific was. The recording 
of the aEEG in the PDE neonate showed a continuous normal voltage pattern with normal 
sleep cycles. Until 48 hour after pyridoxine administration, we did not observe a clear aEEG 
response.
Quantitative analysis of digital EEG recordings
Amplitude:
Digital EEG responses to pyridoxine-IV administration were assessed at central, centro-
temporal, frontal and occipital electrodes. In eight TRS neonates, EEG amplitudes declined at 
central, centrotemporal, and frontal electrodes (p < 0.05) [eight trials; C3-C4 median -20% 
(-82 to -3 %; Fig. Ia); C3-T3: -21% (-78 to -2%); C4-T4: median -17% (-76 to -5%); 
F3-F4: median -6% (-64 to -2%)]. After subdivision according to PDE and non-PDE, 
EEG amplitude alterations similarly declined in both PDE (central decline in PDE: median 
-30% (-78 to -3%; Fig. Ib); and in non-PDE: median: -20% (-45 to -12%; Fig. Ic). At 
occipital electrodes, EEG amplitude alterations did not significantly change. Regarding EEG 
amplitude alterations, stratification according to vigilance levels did not show different 
responses between PDE and non-PDE.
Total power:
In all neonates with TRS, we separately assessed the effect by pyridoxine-IV on total power 
in delta, theta and beta frequency bands (Fig. II). This revealed a decline in total power 
for all frequency bands at central, centro-temporal and frontal electrodes (median declines 
-21%, -17%, -17% respectively; p < 0.05). Subdivision according to PDE and non-PDE did 
not show different responses in total power between both groups [total power decline at 
C3C4 medians (ranges) in: (1) delta-band, PDE: -31% (-77 to -1%) and non-PDE: -16%, 
(-43 to -5%); (2) theta-band, PDE: -27% (-73 to -13%) and non-PDE: -28% (-29 to -17%); 
and (3) beta-band, PDE: -35% (-56 to -8%) and non-PDE: -26% (-54 to -8%)]; Fig. IIa-c. 
At occipital electrodes, total power did not decline in neither of the groups. Stratification 
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according to vigilance levels did not reveal different outcomes in total power between PDE 
and non-PDE. 
Relative power:
In neonates with TRS (both PDE and non-PDE), pyridoxine-IV did not affect relative power 
(percentages before versus after pyridoxine for delta, theta and beta-band: in PDE: 50% 
versus 48%; 33% versus 33% and 16% versus 17% and in non-PDE: 57% versus 59%; 
26% versus 26% and 15% versus 14%, respectively). Relative power did not significantly 
differ between neonates with PDE and non-PDE. Regarding relative power alterations, 
stratification according to vigilance levels and pyridoxine dosages did not show different 
responses between PDE and non-PDE. 
The EEG-response to pyridoxine-IV in PDE
Ia. TRS infants: inter-individual % 
amplitude alteration (median decline 
20%; p < 0.05). Open circles indicate 
PDE neonates, closed circles indicate 
non-PDE neonates.
Ib. PDE: inter-individual % amplitude 
alteration (median decline 30%).
Ic. non-PDE: inter-individual % 
amplitude alteration (median decline 
20%). 
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Figure I.  Decline in EEG amplitude by pyridoxine-IV in TRS infants (p < 0.05). Central 
amplitude responses to pyridoxine-IV are separately indicated for infants with TRS 
(Fig. Ia); PDE (Fig. Ib) and non-PDE (Fig. Ic). At the vertical axis, central EEG amplitude 
alterations are expressed as percentile changes against individual reference values (of 
100%) before pyridoxine IV. At the horizontal axis, administration of pyridoxine IV is 
indicated. The median decline is indicated by an arrow (solid line), at the right side of 
figures Ia-c. The inter individual variability of EEG responses to pyridoxine-IV prohibits 
distinction between PDE (red) and non-PDE (black).
Central amplitude decline (p < 0.05) upon pyridoxine-IV in TRS (subdivided for PDE and non-PDE)
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Discussion
In neonates with TRS, we aimed to determine whether the EEG response to pyridoxine-IV 
can identify PDE by ALDH7A1 gene mutations. To the best of our knowledge, quantitative 
pyridoxine-IV EEG responses have not been systematically investigated before in a 
homogeneous neonatal PDE cohort. Present results indicate that pyridoxine-IV induces 
EEG alterations that are neither highly sensitive nor specific for PDE by ALDH7A1gene 
mutations. 
The ALDH7A1 gene encodes for the enzyme α-aminoadipic semialdehyde (α-AASA) 
dehydrogenase, which is involved in lysine degradation. α-AASA dehydrogenase deficiency 
causes increased levels of α-AASA in body fluids11. α-AASA is in spontaneous equilibrium 
with its cyclic form i.e. L-delta(1)-piperideine-6-carboxylate, and the latter is able to 
“trap” pyridoxal-5-phosphate, resulting in pyridoxal-5-phosphate deficiency11. Pyridoxal-
5-phosphate is a cofactor involved in many metabolic pathways of the brain27. Its function 
as co-factor for the enzymatic conversion of (excitatory) glutamate into (inhibitory) 
GABA16,18,33 could explain why pyridoxine supplementation may attenuate seizures in 
general (i.e. in non-PDE patients). However, it is indicated that CSF glutamate and/or 
GABA concentrations are not unanimously associated with the pyridoxine response27. In 
IIa. delta band: inter individual % of 
total power decline in TRS neonates 
(median decline 18%; 
p < 0.05). Vertical lines indicate 
ranges & medians of PDE and 
non-PDE. Open circles indicate PDE 
neonates, closed circles indicate non-
PDE neonates.
IIb. theta band: inter-individual % of 
total power decline in TRS neonates 
(median decline 27%;  
p < 0.05). Vertical lines indicate 
ranges & medians of PDE & non-PDE. 
Open circles PDE neonates, closed 
circles indicate non-PDE neonates.
IIc. beta band: inter-individual % of 
total power decline in TRS neonates 
(median decline 28%; p < 0.05). 
Vertical lines indicate ranges and 
medians of PDE & non-PDE. Open 
circles indicate PDE neonates, closed 
circles indicate non-PDE neonates.
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Total power decline (p < 0.05) upon pyridoxine-IV in TRS (medians and ranges for PDE and non-PDE)
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Figure II. Decline in total power by pyridoxine-IV in TRS infants (p < 0.05). At central 
electrodes (C3C4), individual alterations are expressed for delta, theta and beta 
frequency bands (Fig. IIa, b and c). Medians and ranges are separately indicated for 
PDE (red vertical line) and non-PDE (black vertical line), at the right side of figures IIa-c. 
In all frequency bands, total power responses to pyridoxine-IV overlapped and did not 
distinguish between PDE and non-PDE.
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accordance with this observation, present digital EEG data did not reflect enhancement of 
specific GABA-ergic characteristics after pyridoxine-IV administration (such as for instance 
increased beta activity34). Hopefully, future studies may further clarify the underlying 
mechanism for seizure reduction by pyridoxine. 
In neonatal PDE, direct EEG alterations by pyridoxine-IV are characterized by attenuation 
of seizure activity and flattening of the trace23,24. However, in the present study, four of 
six PDE neonates lacked such a direct EEG pyridoxine-IV response. Interestingly, one of 
the non-PDE neonates showed an EEG response that appeared characteristic for PDE. 
This specific child had previously been diagnosed with PDE, until normal urinary α-AASA 
levels and absence of ALDH7A1 gene mutation excluded the diagnosis. All together, during 
pyridoxine-IV, visual EEG analysis of the EEG-response to pyridoxine-IV can neither identify 
nor exclude PDE. Regarding the quantitative EEG responses, we observed a trend consisting 
of larger median % amplitude and % total power declines in PDE than in non-PDE infants. 
However, due to the large inter-individual overlap in outcomes, individual identification 
of neonatal PDE among non-PDE is prohibited. One of the strengths of the present study 
is that five of six PDE neonates were diagnosed with the same homogeneous genotype. 
Therefore, we cannot attribute the large inter-individual variability in EEG responses to 
different phenotype-genotype relationships. With the presently available data, one may 
only speculate whether the same results would have been expected in other affected 
neonates with different genotypes. Although this question has to be carefully addressed 
in a later study, the large inter-individual overlap between pyridoxine-IV EEG responses in 
neonates with ALDH7A1 gene mutations appears suggestive for a non-specific effect, i.e. 
regardless of the genotype. Given the preceding, we hypothesize that the EEG response 
to pyridoxine-IV is rather dependent upon other, non-specific, factors such as medication, 
gestational age, encephalopathy, comorbidities, and factors other than on the genotype 
itself.
We are aware that the small number of PDE patients may provide a limitation to this study. 
However, since PDE is a rare condition, we included all six neonates (derived from the 
Dutch PDE cohort) with an available pyridoxine-IV EEG trial. Despite this relatively small 
number of patients, large inter-individual variations in EEG responses already hampered 
identification of PDE among non-PDE. 
In conclusion, present data show that pyridoxine-IV causes non-specific EEG responses 
that neither identify nor exclude PDE caused by ALDH7A1 gene mutations. These data 
implicate that neonates with TRS should continue to receive pyridoxine until PDE is fully 
excluded by biochemical and/or genetic analysis. 
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Chapter III.b
Abstract
Incidental reports suggest that antenatal treatment of pyridoxine dependent seizures 
(PDS) may improve neurodevelopmental outcome of affected patients. Two families with 
PDS are reported, both with two affected siblings. Antenatal treatment with pyridoxine 
was instituted during the second pregnancy in each family (50 and 60 mg daily from 3 and 
10 weeks of gestation, respectively). Perinatal characteristics and neurodevelopmental 
outcome at 4 (Family A) and 12 (Family B) years of age, were compared between the 
untreated and treated child within each family. Meconium- stained amniotic fluid was 
present in both first pregnancies and abnormal foetal movements were noticed in one. 
In the treated infants, pregnancy and birth were uncomplicated. In family A, postnatal 
pyridoxine supplementation prevented neonatal seizures. Both children in family A were 
hypotonic and started walking after 2 years of age; both had white matter changes on MRI, 
and the first child was treated for squint. IQ was 73 and 98 in the antenatally untreated 
and treated child, respectively. The second child in family B developed seizures on the 
seventh day, because pyridoxine maintenance therapy had not been instituted after birth. 
Seizures responded rapidly to pyridoxine supplementation. MRI showed large ventricles 
and a mega cisterna magna. IQ was 80 and 106 in the antenatally untreated and treated 
child respectively. Both children had normal motor development. These results suggest that 
antenatal pyridoxine supplementation may be effective in preventing intrauterine seizures, 
decreasing the risk of complicated birth, and improving neurodevelopmental outcome in 
PDS. 
Keywords: Seizures, Pyridoxine, Antenatal treatment, Development. 
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Introduction
Pyridoxine-dependent seizures (PDS; MIM 266100) is a rare autosomal recessive disorder 
with an estimated birth incidence between 1 in 396 0001 and 1 in 783 0002. PDS has been 
recognised for over 50 years, since the first report by Hunt et al. in 19543. The classic 
presentation of PDS consists of neonatal seizures that are intractable to conventional 
anti-epileptic drugs but adequately respond to pyridoxine (vitamin B6) administration. In 
retrospect, about 20% of mothers report abnormal foetal movements highly suggestive of 
intrauterine seizures4. Birth can be complicated, as a third of the children present with asphyxia 
and/or suspected hypoxic-ischaemic encephalopathy2,4. Not only is PDS characterised by 
seizures but also by encephalopathic symptoms such as agitation, jitteriness, irritability, 
startle reactions and feeding problems4. Reports on cerebral imaging have shown cerebral 
haemorrhage, non-specific white matter abnormalities, hydrocephalus, hypoplasia of the 
posterior part of the corpus callosum, cerebellar hypoplasia and a megacisterna magna5-8. 
At older age, cortical atrophy with ventricular dilation is sometimes observed in affected 
patients5,6,9. 
Until recently, PDS was a clinical diagnosis based upon effective seizure control by 
pyridoxine administration. In 2006, mutations in the ALDH7A1 gene were shown to be 
present in the majority of patients with a clinical diagnosis of PDS10-13. ALDH7A1 encodes 
the enzyme α-aminoadipic semialdehyde (α-AASA) dehydrogenase that plays a role in the 
degradation of the amino acid lysine. α-AASA dehydrogenase deficiency leads to increased 
levels of α-AASA in urine and plasma11 and α-AASA can therefore be used as a biomarker 
for PDS14. There are at least two pathophysiological mechanisms that play a role in PDS. 
First, semialdehydes easily bind to many different molecules and accumulation of α-AASA 
might therefore have toxic effects on the (developing) central nervous system. Second, 
α-AASA is non-enzymatically converted to L-delta(1)-piperideine-6-carboxylate, which is a 
metabolite that binds pyridoxal-5-phosphate (the active B6 vitamer) and as such leads to 
secondary pyridoxal-5-phosphate deficiency11.
Despite successful seizure control with pyridoxine substitution, the majority of surviving 
PDS patients show some degree of cognitive impairment, particularly concerning expressive 
language development. Only around 20% of treated PDS patients are described as having 
a normal development4,15. Reports of a possible relationship between treatment delay and 
cognitive impairment have been inconsistent1,16. Incidental reports of antenatal treatment 
with pyridoxine in a second pregnancy suggest that this approach may be effective in 
controlling intrauterine seizures17 and may improve developmental outcome3,17-22. 
However, only eight cases of antenatal pyridoxine supplementation have been described, 
and with limited follow-up. Furthermore, treatment sometimes only coincidentally aimed 
for multi-vitamin supplementation in low doses and for a limited number of months. The 
importance of long-term follow-up is illustrated by reports of PDS patients showing an 
average development initially, though not based on a formal assessment, but experiencing 
developmental delays at a later stage16,23,24. 
We report two PDS families from the Dutch PDS cohort with long-term follow-up after 
antenatal treatment in a second pregnancy.
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Methods and patients
Currently the Dutch PDS cohort comprises 14 living children (born 1991 - 2007), including 
three families with two PDS patients each. In two of these families, the mother used 
pyridoxine daily during the second pregnancy from the first trimester onwards. Methodology 
and results of α-AASA measurements and ALDH7A1 mutation analysis have previously been 
reported13,14. Table I presents patient data on the clinical course, imaging and outcome. 
Case Reports
Family A, Child 1. A girl was born at term with meconium-stained amniotic fluid and 
Apgar scores of 7 and 8 after 1 and 5 minutes, respectively. She developed clinical seizures 
within 1 hour after birth. Initially, seizures were temporarily controlled by phenobarbitone 
and clonazepam. Pyridoxine 50 mg was administered intravenously when seizures recurred 
on the 4th day of life; after this, seizures ceased within 5 minutes. Subsequently, the girl 
became hypotonic and needed respiratory support for 2 days. All anti-epileptic drugs were 
discontinued after administration of pyridoxine, and no maintenance therapy with pyridoxine 
was instituted. Seven days after the initial administration of pyridoxine, generalised 
seizures recurred. Again, seizures responded to parenteral administration of pyridoxine. 
The girl was diagnosed with probable PDS (patient 101) according to the clinical criteria 
of Baxter2 and maintenance monotherapy with pyridoxine 15 mg/kg/day was instituted. 
In retrospect the mother reported abnormal jerky foetal movements highly suggestive of 
intra-uterine seizures. MRI of the brain on the fifth day of life showed multiple bilateral 
lesions in the white matter on T2, corresponding with cerebral oedema. Diffusion-weighted 
(DW) images showed in general an increased apparent diffusion coefficient (ADC) with 
numerous focal lesions with a decreased ADC, corresponding with a structural abnormal 
cerebral white matter and recent cytotoxic lesions containing increased extracellular water. 
At the age of 5 months a second MRI showed a thin corpus callosum and slight asymmetric 
ventriculomegaly without clear white matter abnormalities. At 3 years of age (in 2006) 
the diagnosis of PDS was proven at the metabolic and DNA level (Table I). At the time of 
this report the child is 5 years of age and seizure-free on pyridoxine monotherapy. She 
is hypotonic and has motor dyspraxia. In addition, she was treated for squint and did not 
walk until the age of 2.75 years. Mental development according to the Snijders-Oomen 
Nonverbal Intelligence Test (SON-R)25 is below average, particularly in expressive language 
skills (Table I). For these reasons, she currently attends a school for special education. 
Family A, Child 2. During the second pregnancy of a son, the mother used pyridoxine 
50 mg/day from the third week of gestation. Pregnancy and birth, as well as the neonatal 
period, were uneventful. From the first day of life pyridoxine supplementation 50 mg/day 
was instituted which was increased to 150 mg/day at 6 months of age. In the first year of 
life no seizures were noticed; at age 1 year the child experienced a febrile convulsion twice. 
At 1.5 years of age (in 2006) PDS was proven at the metabolic and DNA level (Table I). 
At the age of 4 years, he had a right-sided hemi status epilepticus during a febrile period 
with diarrhoea, which was controlled after 200 mg pyridoxine administered intravenously. 
MRI of the brain at age 1.5 year showed bilateral white matter abnormalities and a thin 
genu corpus callosum. He started walking at age 2¼ years. At the present age of 4 years, 
he is slightly hypotonic. His mental development, assessed using the SON-R, is average, 
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although there is a delay in expressive language skills, needing extra support. His MRI still 
shows circumscript bilateral frontal white matter abnormalities. The parents have no other 
children and have an average social economic status.
Family B, Child 1. The first child in this family, a girl, was born with meconium-stained 
amniotic fluid. She developed seizures 2 hours after birth. Pyridoxine 60 mg/day was started 
after the 10th week of life when trials with several anti-epileptic drugs had failed to control 
her seizures26. Ultrasound and CT scan of the brain showed no cerebral abnormalities, 
except for a small haematoma of the tentorium cerebelli. A trial of withdrawal was 
never performed and at 12 years of age PDS was proven at the metabolic and DNA level 
(Table I). At the moment of this report, the child is 14 years old, attends a regular school 
and has a normal motor development. A recent MRI of her brain showed no abnormalities.
Family B, Child 2. The mother used 60 mg pyridoxine daily during her second pregnancy 
from the 10th week of gestation onwards. Pregnancy and birth were uncomplicated. 
Erroneously no pyridoxine maintenance therapy was instituted after birth. The boy 
developed seizures on the seventh day of life, after which treatment was started with 
60 mg pyridoxine daily. Consequently seizures were controlled. At 10 years of age PDS 
was proven at the metabolic and DNA level (Table I). The boy is currently doing well 
and shows no abnormalities on neurological examination; he attends a regular school 
and has a normal motor development. MRI of the brain at age 12 years showed slightly 
enlarged lateral ventricles and some enlargement of the cisterna magna with a normal 
corpus callosum. Table I presents data on the mental development of these children using 
the WISC-III27. The parents have no other children and have an average social economic 
status.
Discussion
In this report on antenatal treatment in PDS, the first child was regarded as the ‘natural’ 
control patient of the antenatally treated second PDS patient in that same family. 
Pyridoxine was well tolerated by the mother and no abnormal foetal movements were 
reported in the antenatally treated PDS patients. Moreover, pregnancy, labour and birth 
were uncomplicated after antenatal treatment with pyridoxine. These observations suggest 
that antenatal treatment of PDS may be an effective treatment to prevent intrauterine 
seizures and reduce birth-related complications4. 
Within each family the same intelligence test was used to compare the sibs. In family A, a 
non-verbal developmental test (SON-R) was used because this test has sound psychometric 
properties and is often used for children with speech problems, as was the case for these 
children. In the second family the WISC-III was used, which measures both verbal and 
non-verbal capacities and is often used to determine intellectual capabilities of children 
attending regular education. The antenatally treated children in both families were shown 
to have better test results than their first-born sibs. This suggests that antenatal pyridoxine 
treatment may improve mental development, although some degree of developmental 
delay remained in the second child of family A. We were not able to compare the outcomes 
Antenatal treatment in two Dutch families with pyridoxine-dependent seizures
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of the affected children to healthy non-affected siblings, since there were none for both 
families. All four parents have attended regular education.
Interestingly, in family B the first child developed clinical seizures 2 hours after birth, 
whereas the second child developed clinical seizures on the seventh day of life. In children 
with PDS who stop pyridoxine treatment, seizure recurrence is usually reported within 
5 - 7 days4,16; suggesting a pyridoxine ‘storage’ sufficient to temporarily prevent seizure 
occurrence in these patients. These observations further suggest that in the present study, 
the second child was adequately treated antenatally and that the pyridoxine dose prevented 
seizures shortly after birth. Conversely, seizure occurrence on day 7 could also reflect the 
different effect of withdrawal in neonates in whom seizure recurrence can be delayed by 
up to 6 weeks16. This observation might indicate what the optimum pyridoxine dose might 
be during pregnancy. Hyperemesis gravidarum is treated with 50 - 100 mg pyridoxine a 
day, which is well tolerated by both mother and foetus16. Others suggested a necessarily 
daily supplement of 2.5 to 10 mg pyridoxine in all pregnant women and have shown 
that the pyridoxine state of the mother significantly affects the foetus28,29. In general, 
only long term use of pyridoxine in doses over 200 - 300 mg a day is thought to lead 
to advers effects, especially reversible sensory neuropathy in healthy adults30. Based on 
these observations we suggest that a daily dose of 50 mg is safe for the mother and may 
prevent foetal seizures, complications at birth, and early neonatal seizures in PDS patients. 
In the present study, MRI of the brain showed abnormalities in 3 of the 4 reported children, 
including in the antenatally treated children. This observation is important and suggests 
that antenatal pyridoxine treatment does not guarantee normal brain development and 
that additional mechanisms (besides seizure-induced injury) may be involved in PDS 
patients. These may include either toxicity due to elevated levels of α-AASA or the lack 
of metabolite(s) after the metabolic block, both of which may cause neuronal damage/
changes irrespective of pyridoxine treatment. In that case, interventions to prevent or treat 
these metabolic changes in PDS patients should be investigated in order to improve future 
outcome in this group. The disappearance of the neonatal white matters abnormalities 
seen in patient 1 (Family A) has been interpreted by us as the result of seizure control. 
This is one of the few reports focusing on antenatal treatment of anticipated/possible PDS 
in a second child, including long-term and case-controlled follow-up. Until now, antenatal 
treatment of PDS has been reported in only 8 patients3,17-22 and two of these reports 
(regarding a family that moved from France to England) might overlap19,21. The reports 
are not uniform regarding the daily antenatal doses, the period of antenatal treatment, 
the reason for treatment, or the reported (side)effects (Table II). No complications at 
birth and no neonatal seizures in the first week of life were reported for any of the treated 
patients. Only four patients were formally tested regarding development outcome, all 
of whom showed some degree of developmental delay. In the remaining four patients, 
developmental outcome was either roughly described as ‘normal’ (n = 3) or ‘delayed’ 
(n = 1). Only one report mentioned a control PDS sib who did not receive antenatal 
pyridoxine treatment; this report concluded that antenatal treatment does not improve 
outcome, although the antenatally treated children scored about 10 IQ points higher than 
the PDS patient that did not receive antenatal pyridoxine21. 
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Because of the autosomal recessive nature of PDS, the recurrence risk is 25% in consecutive 
pregnancies. The metabolic and genetic defect of PDS has recently been elucidated11, which 
gives the opportunity for prenatal diagnostic investigation. In selected families prenatal 
diagnosis and/or antenatal pyridoxine treatment can be offered. Antenatal pyridoxine 
treatment should start as early as possible in pregnancy, and not be postponed until the 
results of eventual prenatal diagnostic tests are available. 
In both families, the affected children were homozygous for the – common – 
c.[1195G > C]; mutation, which has a relatively high frequency in the Netherlands 
(15 of 20 alleles13), and has also been frequently identified by others (12 of 36 alleles12) 
(11 of 30 alleles31). The mutation leads to substitution of glutamate at position 399 by 
glutamine p[Glu399Gln] and is predicted to have a negatively effect on the binding capacity 
of α-AASA dehydrogenase to the required cofactor NAD+, resulting in decreased enzyme 
activity32. 
Intrauterine treatment of a foetus that suffers from a genetic metabolic disorder is rarely 
possible. Our report shows the possible positive effects that can be reached, and it aims 
to increase the awareness of clinicians regarding this ‘unusual’ treatment modality. 
Besides PDS, there are at least three other autosomal recessively inherited metabolic 
disorders that are good candidates for antenatal treatment. In 3-phosphoglycerate-
dehydrogenase deficiency (a disorder of serine biosynthesis) supplementation of L-serine 
has been successful33. Vitamin B12-responsive methylmalonic aciduria can be treated by 
supplementation of the mother with high doses of vitamin B1234. Finally, another defect 
of pyridoxine metabolism, namely pyridox(am)ine-5’-phosphate oxidase, should (at least 
theoretically) be treatable by supplementation of pyridoxal-5’-phosphate, the active form of 
pyridoxine35. The current study is limited by its retrospective nature and the small sample 
size, which is due to the rare nature of PDS. However all previous reports on antenatal 
treatment are case reports, and most do not describe control patients. Prospective studies 
on the effects of antenatal treatment of PDS should be performed. 
We conclude that, after a previous child with PDS, there are strong arguments to supply 
mothers with pyridoxine during subsequent pregnancies. Using this approach, foetal and 
neonatal seizures and birth-related complications in affected sibs may be prevented. 
Finally, our data suggest that antenatal treatment may improve developmental outcome in 
subsequent PDS patients, compared to untreated siblings. 
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Chapter III.c
Abstract 
Aim: The long-term outcome of the Dutch pyridoxine-dependent epilepsy cohort and 
correlations between patient characteristics and follow-up data were retrospectively 
studied.
Method: Fourteen patients recruited from a national reference laboratory were included 
(four males, 10 females, from 11 families; median age at assessment 6 years; range 2 
year 6 months – 16 years). The following data were retrieved: sex; age at seizure onset; 
age at start pyridoxine therapy; level of urinary alpha-aminoadipic acid semialdehyde; 
antiquitin mutations; developmental milestones; evaluation of neurocognitive functioning 
and school career; magnetic resonance imaging (MRI) and electroencephalography (EEG) 
assessments.
Results: Pyridoxine was started antenatally in two children, in the first week of life in five, 
in the first month of life in three, or after the first month of life (range 2.5 – 8 months) 
in four. No children were physically disabled; however, only five walked at 2 years of 
age. Mental development was delayed in most: median IQ or developmental index was 
72 (SD 19). Pyridoxine monotherapy controlled seizures in 10 of 14 children, whereas 
four needed additional antiepileptic drugs. Seizure persistence, antiepileptic drugs (other 
than pyridoxine), EEG background, and epileptiform activity were not associated with 
outcome. On neonatal MRI, structural and white matter abnormalities occurred in five of 
eight children; on follow-up, the number of abnormal MRI was increased. Delayed initiation 
of pyridoxine medication and corpus callosum abnormalities were significantly associated 
with unfavourable neurodevelopmental outcome, but normal follow-up imaging did not 
predict a good outcome.
Interpretation: Outcome of patients with pyridoxine-dependent epilepsy remains poor. 
Individual outcome cannot be predicted by the evaluated characteristics. We suggest that 
collaborated research in structured settings could help to improve treatment strategies and 
outcome for pyridoxine-dependent epilepsy.
Abbreviations
α-AASA Alpha-aminoadipic acid semialdehyde
PDE Pyridoxine-dependent epilepsy
WMA White matter abnormalities
What this paper adds
• Seizure control was reached in all children with pyridoxine-dependent epilepsy, but 
necessitated the use of additional antiepileptic drugs in four.
• Age at start of treatment and corpus callosum abnormalities significantly correlated 
with outcome.
• Normal follow-up imaging did not predict good outcome.
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Introduction
Pyridoxine-dependent epilepsy (PDE) is a rare autosomal recessive disorder1, with an 
incidence of approximately one in 400 000 children in the Netherlands2. The underlying 
metabolic defect in the cerebral lysine degradation pathway, alpha-aminoadipic acid 
semialdehyde (α-AASA) dehydrogenase (antiquitin) deficiency, results in accumulation of 
several metabolites, mainly α-AASA, Δ1-piperideine-6-carboxylate, and pipecolic acid, and 
secondary pyridoxine depletion of the central nervous system3,4. Treatment with pyridoxine 
is rational and generally sufficient to control the seizure disorder.
Despite the recent elucidation of the molecular basis for PDE4 and the rapidly increasing 
number of reported patients since then, detailed data on long-term outcome remain 
scarce. Overall, outcome in PDE is often considered to be poor5. To contribute to the 
understanding of the prognosis of children with PDE, we studied the long-term outcome 
of a previously described cohort of patients with PDE in the Netherlands by standardized 
evaluation of present neurocognitive functioning, and systematic review of all available 
magnetic resonance imaging (MRI) and electroencephalography (EEG) studies. We studied 
possible relations between the acquired follow-up data and the initial patient characteristics 
at diagnosis (i.e. the age at diagnosis, age at start of pyridoxine supplementation, and 
genetic and biochemical data).
Method
For this study, we included all patients with PDE (n = 14: four males, 10 females, from 11 
families; median age at assessment 6 years; range 2 years 6 months - 16 years) diagnosed 
in our (nationwide reference) laboratory and born in the Netherlands between 1991 and 
2008 (Table I). Three families had two affected children; in these families a diagnosis of 
PDE in the first born was made before the birth of the second affected child. In two families 
the mother started daily pyridoxine in the first trimester of her second pregnancy, 60 mg 
(patient 1) and 50 mg respectively (Bok et al.6). PDE was proven in all patients by demonstration 
of increased urinary α-AASA concentrations and mutations in the antiquitin gene3,7. 
α-AASA in urine was measured by liquid chromatography-tandem mass spectrometry as 
previously published4. The following data were retrieved from the medical records of all 
patients: sex; age at seizure onset and age at start of pyridoxine therapy; urinary α-AASA 
level and antiquitin mutations at diagnosis; vitamin B6 intake (milligrams per kilogram); 
developmental milestones such as age at independent walking and school career (regular 
school or special education); and current medication.
All patients underwent a standardized neurocognitive test battery for this study 
(n = 6) or test results were retrieved from the records (n = 8). The Bayley Scales of Infant 
Development (2nd edition, Dutch manual) was used for children below 3 years of age8, 
the Snijders-Oomen Non-Verbal Intelligence Test (Revised) 2.5 - 7 for children between 
2.5 and 7 years of age9, and the Wechsler Intelligence Scale for Children (3rd edition; 
WISC-III) for children between 8 and 17 years of age10. The Wechsler Intelligence Scale 
for Children also provides separate outcomes for performance and verbal IQ. These tests 
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have been judged as sufficient (Bayley Scales of Infant Development) or good (Snijders-
Oomen Non-Verbal Intelligence Test and WICS-III); test results can be compared with 
one another10. Developmental outcome was defined as normal with total development 
index (for the Bayley Scales of Infant Development) or IQ (for WISC-III and Snijders-
Oomen Non-Verbal Intelligence Test) scores above 85 (group 1), mildly delayed with total 
developmental outcome scores between 70 and 84 (group 2), moderately delayed with 
total developmental outcome scores between 55 and 69 (group 3), and severely delayed 
with total developmental outcome scores under 55 (group 4). This definition was used for 
this study and is based (groups 1 – 3) on the Bayley Scales of Infant Development with a 
subdivision of group 4 with severely delayed development8. SD was set at 15 IQ points. 
The median age at assessment was 6 years (range 2.5 – 16 years).
We collected all available MRI and EEG recordings of the 14 children with PDE. As MRIs and 
EEGs were collected over a period of 15 years from eight different Dutch centres, different 
machines and protocols had been used for MRI and EEG recordings. Although most of 
the MRIs were retrospectively collected and not done for this study, most MRI studies 
were extensive. Minimally studied MRI sequences included axial T1 and T2 and sagittal T1 
images. All MRIs had been evaluated by a neuroradiologist in the original centre and were 
Chapter III.c
Patient Male/
female
Seizure 
onset
Start B6 α-AASA urine  
(mmol/mol  
creatinine)
DNA mutation
1a M Not Antenatal 20 c.[1195 G > C]+[1195G > C]
2b M Not Antenatal 75 c.[1195 G > C]+[1195G > C]
3 F 1 d 16 d 32 c.[1195 G > C]+[1195G > C]
4 F 5 d 6 mo 5 c.[750G > A]+[1348T > A]
5a F 1 d 2.5 m 29 c.[1195 G > C]+[1195G > C]
6c F 2 d 10 d 16 c.[1195 G > C]+[1195G > C]
7b F Intrauterine 5 d 39 c.[1195 G > C]+[1195G > C]
8 F 3 d 2.5 mo 4 c.[750G > A]+[750G > A]
9 F 2 d 5 d 99 c.[1195 G > C]+[1195G > C]
10 M 2 d 13 d 60 c.[1195 G > C]+[1195G > C]
11 F 0 d 3 d 71 c.[1195 G > C]+[1195G > C]
12c F 2 d 3 d 24 c.[1195 G > C]+[1195G > C]
13 F 1 d 8 mo 10 c.[1195 G > C]+[1195G > C]
14 M 1 d 3 d 12 c.[1195 G > C]+[244C > T]
M, male; F, female; α-AASA, alpha-aminoadipic acid semialdehyde; a,b,cpair of sibs (1 and 5; 2 and 7; 6 and 
12); reference ranges for urinary α-AASA: ≤ 6 months, < 2 mmol/mol creatinine; > 6 months to 1 year, 
≤ 1 mmol/mol creatinine; > 1 year, ≤ 0.5 mmol/mol creatinine 
Table I.  Characteristics of patients with pyridoxine-dependent epilepsy
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reviewed and scored separately by two investigators (LAB and MAW). A structured method 
was used by the investigators to study all MRIs.11 A mega cisterna magnum was defined 
as a distance of more than 10 mm, and an enlarged cisterna magnum as a distance of 
5 to 10 mm, between cerebellum and skull. All EEGs were qualitatively assessed by two 
investigators (DAS and JHvdH). We applied the term ‘epileptiform’ activity for interictal 
sharp waves (i.e. peaked configurations at paper speed 70 – 200 ms, observable in theta 
and/or delta frequency bands). We reserved the term ‘discrete’ epileptiform activity to 
denote sporadic, isolated sharp waves at a frequency of fewer than 10 per 30 minutes. 
The study was approved by the institutional review board of Màxima Medical Centre, 
Veldhoven, the Netherlands. Signed, informed parental consent was obtained to collect the 
studied data.
Statistical analysis
A Mann–Whitney U test and Fisher’s exact test were used to analyse non-parametric 
divided numeric and categorical data respectively. Significance was defined as p < 0.05. 
Spearman’s correlation coefficients were estimated.
Results
Neurodevelopmental outcome
Test results are summarized in table II. All 14 children had learned to walk independently 
(mean age 26 months); however, only five children could walk independently before the 
age of 2 years. No child was physically disabled and all of the children were in level I of the 
Gross Motor Function Classification Score. Six children attended regular school; three of 
these children needed extra support at school. Eight children attended a school for special 
education. One child had been treated for hydrocephalus by third ventriculostomy.
Normal cognitive development (IQ or developmental index > 85) was seen in four 
children, mildly delayed development (IQ or developmental index 70 - 84) in four children, 
moderately delayed development (IQ or developmental index 55 - 69) in three children, 
and severely retarded development (IQ or developmental index < 55) also in three 
children. Mean IQ was 72 (SD 19; median IQ 72). Performance versus verbal IQ was 
tested in five children. In four of these children, verbal IQ was higher than performance 
IQ. In only one patient did this difference reached significance of more than one SD. 
In six children between 3 and 7 years of age a pretest assumption of poorly developed 
Verbal skills was made by the psychologist, and subsequently a developmental test, the 
Snijders-Oomen Non-verbal Intelligence Test, was chosen. This implied that comparison 
between Verbal and Performance IQ could not be studied in these children. Although in 
most reports the psychologist made some remarks about the behaviour of the studied 
child, we did not perform a structured systematic behavioural study in the children with 
PDE. The remarks on behaviour were normal behaviour (n = 9), good concentration 
(n = 10), not well concentrated (n = 2), dyspraxia (n = 3), timid (n = 2), dysphasia 
(n = 1), unknown (n = 2).
Long-term outcome in pyridoxine-dependent epilepsy
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Neuroimaging
Neonatal MRI
Neonatal T1- and T2-weighted MR images were available for analysis for eight children; 
in four children additional diffusion-weighted images were available, and in one child we 
assessed neonatal CT images. Corpus callosum was normal in five children, dysplastic in 
two (splenium), and hypoplastic in one child. Neonatal intracranial, subdural haemorrhage 
in the vicinity of the falx and tentorium cerebri was observed in three children. On T1 and 
T2, no distinctive white matter abnormalities (WMA) were seen, except in one patient. 
However, diffusion-weighted images revealed abnormal signals in all four studies. Lesions 
with an increased apparent diffusion coefficient were predominantly located in the frontal 
and parietal regions. In two neonates, small focal lesions with decreased apparent diffusion 
coefficient, next to extensive regions with increased apparent diffusion coefficient, were 
seen.
Follow-up MRI
In 13 children MRI could be studied after the neonatal period (range 3 months – 16 years of 
age; table II). Structural anomalies were still present on follow-up MRIs in all patients with 
neonatal MRI anomalies. One patient had a mega cisterna magnum on follow-up that was 
not observed at the time of neonatal imaging; this was the patient who required shunting. 
Taking all radiologic data together, the corpus callosum was normal in seven children, four 
had a hypoplastic posterior part (isthmus) and three had an abnormal dysplastic posterior 
part (splenium) of the corpus callosum. Ventriculomegaly was observed in six children. Four 
had a normal ventricular size on their neonatal MRI. In the other two children, neonatal 
MRI was unavailable. In three children with ventriculomegaly, MRI suggested the presence 
of a narrow aqueduct.
In five children, WMA were present on T2-weighted imaging as discrete, multifocal lesions 
(predominantly) in the periventricular and/or central zone. WMA were located at frontal 
(n = 3), parietal (n = 1), or occipital zones (n = 1). On follow-up, diffusion-weighted 
images and apparent diffusion coefficient were normal in all children. A mega cisterna 
magnum was seen in one child. An enlarged cisterna magnum was seen in three children.
Focal signal abnormalities
An abnormal focal MRI signal was seen in the globus pallidus (hypointense on T1) in one 
child, in a cerebellar peduncle (hyperintense on T2; Fig. I) in two children, and in the 
frontal subcortical white matter in one child (hyperintense on T2; Fig. I). In this last child 
there was a slight increase in size over time. A unilateral periventricular cyst (4 mm) just 
above the frontal horn was seen in one child, and a bone cyst was observed in the orbital 
bone of another.
EEG characteristics
Neonatal EEG characteristics have been described previously12. At follow-up, EEG 
background activity had normalized in 12 of 14 children (Table III). Only in one patient 
did we observe polymorphic spike wave-like activity (child 3). In five children epileptiform 
activity was absent, in five it was only discrete, and in four it appeared more pronounced. 
Epileptiform activity was located at frontal (in five children), fronto-central (in three), 
temporal (in one), or central (in one) regions.
Long-term outcome in pyridoxine-dependent epilepsy
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Patient characteristics in relation to developmental outcome
Start of treatment
Children treated antenatally had a higher IQ than their siblings and had the highest 
IQ scores in group 1. Outcome of antenatal treatment versus postnatal treatment was 
significant in this group. Of the eight children who were treated in the first month of life, 
five revealed a developmental outcome in group 1 or 2, and three in group 3 or 4. Of the 
five children who were treated after 2.5 months of age, two showed a developmental 
outcome in group 1 or 2, and three in group 3 or 4. One patient who was only treated after 
6 months of age had severely delayed development. Although there was no significant 
correlation between long-term neurodevelopmental outcome and age at which treatment 
was initiated, we observed a suggestive trend in favour of early treatment initiation. No 
pyridoxine daily doses were changed after 1 year of age.
Chapter III.c
Figure I.  Axial fluid-attenuated inversion recovery image of patient 2 showing bifrontal 
subcortical hyperintense signal abnormalities
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Genotype outcome
Three children had a different mutation than the common Dutch one (Table I): two had a 
developmental outcome in groups 1 or 2, the other in group 4 (not significant).
Seizure onset, persistence of epilepsy or EEG abnormalities, use of antiepileptic 
drugs
Because all PDE seizures had started during the first few days of life, we did not observe 
a relation between seizure onset and developmental outcome (Table III). The persistence 
of seizures, the use of antiepileptic drugs (other than pyridoxine), the EEG background 
activity, and presence of epileptiform activity appeared to be unassociated with outcome.
MRI and developmental outcome
Of the seven children with an abnormal corpus callosum, five had a development outcome 
in group 3 or 4, whereas of the seven children with a normal corpus callosum only one child 
had a development outcome in group 3 (abnormal or normal corpus callosum versus IQ or 
developmental index less or more than 70; significant). No data were available to determine 
an association between corpus callosum abnormalities and Verbal or Performance IQ.
Other parameters and developmental outcome
There was also no statistical relation between outcome and urinary α-AASA levels at 
presentation, outcome and daily pyridoxine dose, or outcome and head circumference. 
Intellectual outcome was related to age at independent walking.
Discussion
In the Dutch PDE cohort, we aimed to elucidate the underlying relationship between 
clinical, radiological, electrophysiological, and biochemical parameters in developmental 
perspective. In this present cohort, all children had the classic phenotype of PDE with 
seizure onset shortly after birth, and most patients shared the same genotype. None 
of these children suffered from severe motor disturbances and all had learned to walk 
independently. The individual courses of intellectual development showed a wide range 
and most patients suffered from a delayed development, which is in accordance with the 
literature. In 10 of 14 children, seizures were well controlled with monotherapy pyridoxine, 
and four of 14 children received long-term treatment with additional antiepileptic drugs, 
also reported by others13,14. Outcome was significantly correlated with corpus callosum 
abnormalities and antenatal start of pyridoxine treatment.
A relatively high prevalence of structural anomalies and WMA was seen on neonatal MRI, 
including one antenatal treated patient, which raises the question whether structural MRI 
abnormalities should be explained as an intrinsic part of the phenotype or as phenomena 
that are secondary to metabolic disturbances or treatment failure. Although corpus callosum 
abnormalities appeared associated with unfavourable neurodevelopmental outcome, a 
normal MRI at follow-up did not warrant good outcome.
So far, cerebral MRI characteristics have been described in 50 patients4,15–18. In these 
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patients, structural anomalies like corpus callosum hypoplasia, mega cisterna magnum, 
as well as non-specific multifocal T2 WMA, cerebral atrophy, and hydrocephalus, are 
common findings. However, a normal MRI does not exclude PDE. In accordance with the 
literature, we also observed frequent MRI anomalies, involving structural corpus callosum 
abnormalities in half of the studied children. Although corpus callosum abnormalities have 
been described before (especially a thin posterior part15), the dysplastic shortening of the 
corpus callosum is a new finding.
Although the presence of ventriculomegaly in PDE has been reported incidentally, no data 
exist on its prevalence. In this cohort it was seen at follow-up in six of the studied children. 
Interestingly, ventriculomegaly was present in a neonate who had received prenatal 
treatment, and in some children ventriculomegaly developed after the neonatal period. In 
three of the six patients, ventriculomegaly coincided with an apparently narrow aqueduct, 
even necessitating shunting of the cerebrospinal fluid in one. Although these numbers 
are small, it appears advisory to monitor children with PDE for development of raised 
intracranial pressure.
In four out of nine neonates with PDE, we observed WMA (indicated by abnormal 
diffusion-weighted images with increased apparent diffusion-coefficient signal intensity). 
Interestingly these transient diffusion-weighted images/WMA, which are not uncommon in 
vasogenic edema, were mainly frontally located, whereas moderate to mild epileptiform 
activity was also frontally located. It remains speculative whether these morphological and 
functional abnormalities of frontal (white and grey) matter are associated and whether 
they should be regarded as common features of the underlying metabolic and epileptic 
encephalopathy.
In contrast to others14, we were unable to demonstrate a relation between epileptiform 
activity, persisting seizures (including antiepileptic drugs) and neurodevelopmental 
outcome. This can be explained by the strong normalizing trend of follow-up EEGs, which 
have been described before16,19,20. The finding that early (postnatal) initiation of pyridoxine 
treatment does not sufficiently save the patient from long-term neurocognitive deficits, and 
the occurrence of different MRI abnormalities at different ages (i.e. at fetal [structural], 
neonatal [transient], and older age), may reflect the complexity of the underlying 
pathophysiological mechanisms of PDE6.
The wide range of developmental outcome in this PDE cohort is in accordance with the 
literature. We have reviewed developmental outcome data of 93 patients with PDE that 
we found in the literature4,15–17,20–26. In those studies (five) that presented quantitative 
data on IQ15,21,23,25,26 (a total of 24 patients), mean IQ was 68, comparable to our data. 
Using less detailed developmental scores for categorizing patients in whom exact data 
were lacking (i.e. normal versus mild, moderate, or severe delay) revealed similar results: 
normal development was seen in 25% (n = 24), mildly delayed in 27% (n = 25), moderately 
delayed in 24% (n = 22), and severely delayed development in 24% (n = 22).
Interesting results were found for the outcome of Verbal versus Performance IQ. In the 
normal population, Performance IQ equals Verbal IQ. In the literature, 17 of 24 patients 
Long-term outcome in pyridoxine-dependent epilepsy
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with PDE in whom Verbal and Performance IQ data were studied, Performance IQ was 
significantly higher than the Verbal IQ15,21,23,25,26. In the present study, Verbal IQ exceeded 
Performance IQ in the tested children. These test results do not support the findings of 
others15 who found a poor development of expressive language skills. These discrepancies 
with PDE indicate that ongoing testing during development in each PDE patient is important.
Owing to the low prevalence of PDE, the studied cohort was small. This makes statistical 
analysis difficult and less sensible, and conclusions limited (low power). In addition, the 
retrospective character of this study, at least in the acquisition of most clinical, radiological, 
and EEG data, as well as disease course during the neonatal period and early development, 
precludes firm conclusions. Enlarging the number of patients, for example by combining 
cohort databases, and structured prospective follow-up will provide better insight in the 
clinical course of PDE, and its correlation with different clinical, metabolic, and radiological 
parameters. Only when we learn more about the long-term course of the disease will we 
be able to optimize already available treatment options (pyridoxine supplementation) and 
to develop novel (e.g. dietary) interventions.
Chapter III.c
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Summary
Pyridoxine Dependent Epilepsy (PDE) is a rare metabolic1 defect in the degradation of 
lysine. The authors report a patient with metabolic and DNA confirmed PDE, on the fifth 
day of life opthalmoscopy showed bilateral multiple white centered retinal haemorrhages, 
so called Roth Spots. Roth spots are non-specific haemorrhagic signs that occur in a variety 
of conditions of acute systemic insults in homeostasis - most often infections - which 
relate to retinal capillary damage and the ensuing reparative process. No biochemical or 
microbiological signs of infection were present in blood and cerebrospinal fluid. MRI of the 
brain showed an abnormal diffusion signal with increased apparent diffusion coefficient 
and little blood around the tentorium. The knowledge of the pathogenesis of PDE is still 
limited. The presence of Roth spots is suggestive for a pathogenic mechanism of vasogenic 
damage in PDE.
Background
In this paper we report for the first time a patient with metabolic confirmed pyridoxine 
dependent epilepsy (PDE) and Roth spots. PDE is a rare metabolic defect in the degradation 
of lysine. This metabolic defect leads to the accumulation of α-aminoadipic semialdehyde 
(α-AASA) and indirectly to an inactivation of pyridoxal-5-phosphate, the active metabolite 
of pyridoxine (vitamin B6). The most striking symptom of PDE are seizures which do 
not respond to conventional anti-epileptic drugs but respond to pyridoxine. Knowledge 
of the clinical spectrum and associated abnormalities of PDE is rapidly expanding since 
the detection of the underlying metabolic defect and its genetic basis2-4. Although squint 
is seen in 30%5-7 and optic nerve hypoplasia is reported in two patients7, other true 
ophthalmologic abnormalities are rarely reported. Roth spots are suggestive for vasogene 
damage, and they might be a clue for a pathologic pathway in PDE. Therefore we believe 
our data could be of important additional value. 
Case presentation
A male newborn, born after an uneventful pregnancy and delivery, was admitted with 
generalized seizures 12 hours after birth. The convulsions were unresponsive to 
anticonvulsants but subsided with 100 mg pyridoxine intravenously. As can be expected 
in PDE, the first dose of pyridoxine led to severe respiratory depression, necessitating 
mechanical ventilation during a short period. The boy was clinically diagnosed with PDE on 
the second day of life. This diagnosis was confirmed by demonstration of highly elevated 
α-AASA levels in the urine [37 mmol/mol creatinine; N < 2 mmol/mol creatinine] and a 
homozygous 1195 G > C antiquitin mutation. Ophthalmoscopy on the 5th day of life showed 
multiple white centred retinal haemorrhages, so called Roth spots, in both retinas (Fig. I). 
On follow-up these Roth spots gradually disappeared within a few months. No biochemical 
nor microbiological signs of infection were present in blood and liquor, bacterial cultures 
and viral antigens (toxoplasmosis, rubella, CMV, herpes and HIV) remained negative. Brain 
MRI showed some blood on the tentorium and on the falx cerebri and an abnormal diffuse 
signal with increased Apparent Diffusion Coefficient.
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Roth spots in Pyridoxine Dependent Epilepsy
Figure I.  Fundusphoto of the nasal side of the right eye, in the peripheral retina is 
multiple Roth spots (white centered retinal dot haemorrhages)
Discussion
The observed Roth spots are rare ophthalmologic abnormalities, different from more 
common neonatal intra-retinal haemorrhages which are flame shaped and/or dot blot 
haemorrhages often related to the delivery8. These common postnatal retinal haemorrhages 
resolve usually within days9. Retinal haemorrhages occasionally described in metabolic 
diseases10-17, are not reported as Roth spots. 
Roth spots are non-specific hemorrhagic signs that occur following a variety of conditions. 
These conditions have in common an acute disturbances of the homeostasis contributing 
to retinal capillary damage and the ensuing reparative process18,19. Usually and most 
often, Roth spots are seen in patients with sub-acute bacterial endocarditis. They may also 
occur in several other conditions such as other infectious diseases and perinatal hypoxic 
encephalopathy. These were excluded in this patient18,20.
Whether the observed Roth spots are coincidentally found in this patient with PDE, or are 
directly related to PDE is not clear. We can only speculate whether there is an association 
of Roth spots with PDE. Roth spots or retinal haemorrhages have never been reported in 
patients with PDE (with PLP inactivation and α-AASA accumulation) or in other patients 
with pyridoxine responsiveness, e.g. hyperprolinemia type II or hypofosfataemia. A direct 
relation of the Roth spots with the seizures or the anti-epileptic drugs, including pyridoxine, 
also remains speculative. 
Learning Points
Ophthalmoscopy should be done in PDE patients.
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General discussion and future perspectives
Pyridoxine Dependent Epilepsy (PDE) (MIM#266100) is an autosomal recessive disorder of 
lysine metabolism, caused by mutations in the ALDH7A1 (antiquitin) gene on chromosome 
5q31. Classically, PDE presents as a severe neonatal epileptic encephalopathy, with 
seizures that appear resistant to anti-epileptic drugs until the moment that pyridoxine is 
administered. In the general discussion of this thesis epidemiological, pathophysiological 
(biochemical, molecular genetic), diagnostic and outcome of treatment aspects will be 
discussed.
Epidemiology of PDE in the Netherlands
PDE is a very rare disease. Epidemiological data on PDE are limited and regional differences 
in PDE are reported1,2. In 2005 we calculated a birth incidence of 1:390 000 for clinical 
defined probable and definite PDE in the Netherlands3. During the course of our study it 
became clear that the true incidence of PDE in the Netherlands may be (much) higher than 
previously thought, namely 1:200 000 born children.
The apparent increase of incidence, suggests that in the past PDE may have been under-
diagnosed. This is supported by the fact that no patients born before 1991 are reported 
(national survey of all adult neurological departments in the Netherlands in 2006, 
unpublished data).
The apparent increase in the incidence of PDE in the Netherlands may be related to several 
factors. Nowadays PDE is confirmed by a metabolic test and if this test is abnormal it is 
followed by DNA examination to prove the diagnosis at the genetic level. The laboratory 
confirmation opens the possibility to collect data in a database and probably get a better 
impression of the incidence and the full spectrum of this rare disorder. There is also an 
increased awareness, which is reflected by the implementation of a national protocol on 
neonatal seizures in the Netherlands. This protocol recommends to transfer a neonate 
with persistent seizures to a neonatal intensive care unit, and describes the diagnostic and 
treatment procedures (www.nvk.nl). 
Although PDE is a very rare disease, the estimated total number worldwide is significant. 
If the birth incidence of 1:200 000 of PDE in the Netherlands would be applied on a 
world wide population of 7 billion people and a world birth rate in 2011 of 19 per 1000 
(wikipedia), the birth incidence would be about 600 patients per year world wide. 
 
Pathophysiology
Vitamin B6 is known since 1934, when György described a B factor that cured rat dermatitis. 
Vitamin B6 is a mixture of metabolites with several biological forms: pyridoxine, an alcohol 
(pyridoxol), an aldehyde (pyridoxal) and a form with an amino group (pyridoxamine), and 
their 5’-phosphate esters. Pyridoxine, pyridoxal and pyridoxamine-phosphate are oxidized 
to pyridoxal-5-phosphate (PLP) by pyridox(am)ine 5-phosphate oxidase (PNPO). PLP is 
the biological active form of vitamin B6. All these metabolites are generally described as 
if it were one metabolite, ‘pyridoxine’. PLP functions as a cofactor in at least a hundred 
biochemical reactions.
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In various animal experiments it has been shown that removal of pyridoxine from the diet 
results in a set of signs including dermatitis, anaemia and neurologic manifestations. Severe 
convulsions occur in chickens, swine’s, calves and ducks. Deficient mice also can have an 
ataxic gait, and ducks can have difficulty in standing and paralysis of the legs. In monkeys 
extensive arterial lesions were found, which closely resemble human arteriosclerosis4. 
Deficient rats had opacity of the cornea5. Around the year 1950 a vitamin B6 deficient milk 
formula came to the market due to an error during the production process. Several infants 
that were fed with this formula developed pyridoxine deficient-like symptoms i.e. initially 
hyperirritability and apparent gastrointestinal colic, with regurgitation, followed by tonic 
posturing and generalized seizures. Hyperreactivity to sound, movement and feeding was 
also noted, which could precede seizures6,7. 
In 1954 Hunt suggested that PDE could best be ‘described as an unusual metabolic 
aberration of the central nervous system in which there is a continuing high requirement 
of pyridoxine in excess of the normal dietary intake in order to maintain this infant in 
a seizure free state’8. In 1960 Scriver ruled out that renal loss alone could explain the 
findings in PDE and suggested an increased B6 requirement of the brain9. 
Previously it was suggested that the pathophysiology of PDE was related to glutamic acid 
decarboxylase which requires PLP to synthesize (inhibitory) gamma-amino-butyric acid 
(GABA) from (excitatory) glutamate10. However abnormalities of this enzyme were ruled 
out in 200011. Others suggested a transport disorder of cellular B6 within the central 
nervous system but this hypothesis could not be proven in humans. 
In 2000 Cormier-Daire et al. found linkage to chromosome 5q31, but a disease-causing 
gene was not identified12. Plecko et al reported elevations of pipecolic acid in plasma and 
CSF, which persisted after treatment, but the explanation for this finding was unclear at 
that time13. Finally in 2006 Mills et al demonstrated that PDE was caused by mutations in 
the ALDH7A1 or the so called antiquitin gene indeed linked to chromosome 5q3114. The 
definition of the underlying defect as an inborn error of cerebral lysine degradation explained 
the different previous findings of pipecolic acid elevations, pyridoxine dependency, and 
seizures.
Although the genetic and metabolic causes of PDE have been unravelled, the ‘PDE conundrum’ 
is only partly unravelled6 as the pathophysiology of PDE is not totally clear. In theory the 
pathophysiology in PDE is determined by different mechanisms like pyridoxine deficiency, 
accumulation of lysine metabolites (‘intoxication type inborn error of metabolism’), and as 
the consequence of intrauterine or neonatal seizures. 
Pyridoxine is known as a cofactor in the conversion of glutamate (excitatory) into 
GABA10,15,16. Pyridoxine deficiency may in some cases lead to GABA deficiency which is 
thought to be an important explanation for the occurrence of neonatal seizures in PDE 
patients. Many other enzymatic reactions need PLP as a co-factor, and toxicity or deficiency 
of a variety of other substrates might thus contribute to the pathogenetic mechanisms 
underlying the seizure disorder in PDE. The most imaginative example might be the glycine 
cleavage system that relies on PLP for glycine degradation. Pyridoxine is also known as a 
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cofactor in the sphingolipid synthesis17,18. Therefore pyridoxine deficiency might influence 
sphingolipid formation which may be responsible for white matter abnormalities seen on 
MRI in PDE patients19. Finally pyridoxine deficiency can result in extensive arterial lesions 
as has been observed in animals5. This might account for the cerebral haemorrhages seen 
in several patients19 and the Roth spots we observed in one patient20. 
Accumulation of the potentially toxic lysine metabolites α-AASA, Δ1-piperideine 6-carboxylic 
acid (P6C), and pipecolic acid is another possible pathophysiologic mechanism in PDE. This 
accumulation of lysine metabolites is measurable in all body fluids21,22 including α-AASA in 
amniotic fluid (unpublished data). Accumulation in the central nervous system may lead 
to neural cell damage and this might explain that about a third of patients are not seizure 
free with pyridoxine mono-therapy. Accumulation may also explain the observation of 
(sometimes progressive) MRI abnormalities in some PDE patients, like ventriculomegaly and 
white matter abnormalities19, even in antenatal treated patients23. Importantly, pyridoxine 
supplementation decrease the amounts of accumulated lysine metabolites13. The impact 
of dietary lysine restriction, aiming to further decrease accumulation of lysine metabolites 
has to be studied. The first observational study with lysine restriction is promising and will 
be discussed below24.
Like some other metabolic diseases PDE can result in cerebral malformative consequences. 
For instance, brain malformations can be observed in Congenital Disorders of Glycosylation25, 
Smith-Lemli-Opitz syndrome26, peroxisomal disorders27 and others. The observed brain 
development abnormalities in PDE are Corpus Callosum Dysgenesia, Mega Cisterna 
Magnum and focal lesions as in the globus pallidus, peduncle cerebellum, sub-cortex and/
or skull-bone19. 
In conclusion, although PDE is nowadays known to be caused by a disturbance of the 
lysine catabolism in the cerebral nervous system our knowledge of the pathophysiology of 
PDE is still limited. Further research is necessary to increase our insights in the underlying 
disease mechanisms. Better understanding is required to improve treatment strategies and 
long-term outcome of patients with PDE. 
Diagnosis of PDE 
After the first publication by Hunt in 1954, neonatologists and paediatric neurologists kept 
struggling to identify PDE in patients with therapy resistant seizures8. The development of 
clinical criteria was very useful, and supplied the clinician with some help in the differential 
diagnostic work-up and choices with regard to treatment28. Baxter defined definite PDE as 
neonates, infants, or young children with recurrent (two or more) seizures of any type that 
ceased within seven days after the administration of oral pyridoxine (usual dose, 30 mg/kg/
day, minimum dose, 15 mg/kg/day) or within 30 minutes of intravenous pyridoxine (usual 
dose 100 mg, minimum dose, 50 mg), and recurred when pyridoxine supplementation was 
withdrawn, re-introduction of pyridoxine should finally cease the seizures again. Possible 
cases were defined as above, but without attempt to withdraw and re-introduce pyridoxine. 
Recurrence of seizures while receiving pyridoxine treatment was an exclusion criterion, 
unless the recurrence occurred during a febrile illness. Two subgroups were defined as 
probable PDE because no formal trial of withdrawal was undertaken. In one subgroup, 
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seizures stopped after a single dose of pyridoxine, recurred later, and again responded to 
pyridoxine, which was then continued. A second subgroup comprised of children with an 
affected sibling whose seizures began at the same age and responded to pyridoxine.
Although clinical criteria were often helpful, identification of PDE remained difficult in about 
a third of patients10,29.
Pitfalls in clinical diagnosis
Pitfalls in the diagnostic process of PDE are common. Several studies are presented in this 
thesis21,30 that show the problems to identify or to exclude PDE in patients with therapy 
resistant seizures (TRS), when only clinical criteria are available. One of these pitfalls is 
that some neonates with TRS due to PDE present with problems that are very common 
in neonatal intensive care units like hypoxic ischemic encephalopathy, hypoglycaemia or 
neonatal cerebral haemorrhage. In those cases, these conditions may be considered the 
full explanation of the TRS while they are in fact only secondary to the underlying disorder 
PDE30. Some children with PDE present with feeding problems while seizures develop only 
later10. Some children with PDE have specific EEG features while in others the EEG is 
normal prior to the first gift of pyridoxine, despite clinical seizure activity3. In most patients 
with PDE, seizures start in the first week of life, but in some children seizures only start 
several months after birth. Although most patients do not respond to anti-epileptic drugs 
at all, some have a good initial clinical response on first line anti-epileptic drugs such as 
phenobarbitone, midazolam and/or phenytoin10,31,32. Most, but not all patients respond 
to the first gift(s) of pyridoxine with a dramatic decrease of seizure frequency. Not only 
patients with PDE, but also infants with other epileptic encephalopathies may benefit from 
pyridoxine supplementation30,33,34. Paradoxically, however an increase of seizure activity 
following pyridoxine therapy has also been reported in children with epilepsy due to other 
causes than PDE35,36. 
Some children need a large first dose of pyridoxine, up till 500 mg, before a response 
occurs and seizures disappear31 (this Thesis) and in some children the EEG normalizes 
only 5 days after the first pyridoxine dose30. Notably, about 30% of children with PDE 
do not remain seizure-free on a maintenance dose of pyridoxine but require additional 
conventional anti-epileptic drugs19,37,38. Some children benefit from additional folic acid 
supplementation and some PDE patients even have been treated successfully with mono-
therapy folic acid (see also discussion below)39. In summary, considering all mentioned 
pitfalls and the diverse clinical picture, the diagnosis of PDE on clinical criteria is difficult in 
a significant proportion of patients. 
In this thesis we performed metabolic studies21 in clinical diagnosed PDE patients3. In 
most patients with definite, possible or probable PDE, α-AASA dehydrogenase deficiency 
was demonstrated. Metabolic examination of urine, to determine the concentration of 
α-AASA, proved to be a reliable tool to confirm or to exclude PDE. The assumption is that 
the sensibility and specificity of elevated concentrations of urinary α-AASA are high. It is 
important to note that α-AASA, which was initially thought to be a specific and unique 
marker for PDE, has recently been found elevated in both molybdenum cofactor deficiency 
and isolated sulphite oxidase deficiency40. This finding has to be taken in account for 
diagnosis and treatment in patients with neonatal therapy resistant seizures. An advantage 
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of metabolic examination is that the potentially dangerous ‘trial of withdrawal of pyridoxine’, 
classically used to prove PDE, can now be avoided. Metabolic testing for PDE is therefore 
advised in all children till the age of 18 months with therapy resistant seizures. 
Intra-uterine diagnosis of PDE is challenging. DNA examination of the foetus is possible 
after amniocentesis or chorionic villi biopsy, which are invasive procedures, and as such not 
without risks for the mother or the foetus. We recently investigated the urine of a pregnant 
woman who was carrying a foetus that was potentially affected with PDE, and who used 
pyridoxine during this second pregnancy. Her first child was diagnosed with (metabolic and 
DNA confirmed) PDE. Examination of the maternal urine sample showed no increased of 
α-AASA levels (not published). After birth pyridoxine treatment of the child was continued 
and PDE was diagnosed by demonstrating increased α-AASA concentrations in the baby’s 
urine, and two mutations in the ALDH7A1 gene. 
In neonates with TRS, whether or not due to PDE, intravenous treatment with pyridoxine 
induces EEG changes. These changes were found neither sensitive nor specific for PDE30. 
This study demonstrated that the EEG response to pyridoxine should be interpreted with 
caution and it was concluded that, irrespective of the EEG response to pyridoxine, neonates 
and infants suspected from PDE should continue to receive pyridoxine until PDE is diagnosed 
or excluded by biochemical and/or genetic analysis. New technical developments regarding 
digital analysis of EEG’s, in particular (automated) quantification of multichannel EEG’s 
might provide novel tools to study PDE41-43.
Outcome and Treatment / Outcome of Treatment
Now that the cause of PDE has been identified and some ideas about underlying disease 
mechanisms and additional possibilities for treatment are formulated (see above), future 
studies should be focused on long-term outcome. Long term outcome of PDE patients is 
not invariably good. Our patient cohort, as other cohorts, showed that most patients are 
intellectually disabled: roughly 75% of them having an IQ < 85. About two-third of PDE 
patients attend schools for special education19,37,38. About 30% of patients need anti-
epileptic drugs besides pyridoxine. Another important issue is that too little is known about 
optimal treatment schedules (including optimal daily dose of pyridoxine, see below) in 
relation to outcome19. At the moment most PDE patients receive a daily dose of 15 to 30 
mg/kg/day, in fact based on expert opinion or experiences in single cases or small series29. 
In 1996 the optimum daily dose of pyridoxine was studied in a small cohort (n = 6). A daily 
dose of less than 2 mg/kg appeared to be insufficient. A marked improvement of IQ and 
behaviour was seen in some patients after increase of the daily dose1. However we could 
not find a relation between pyridoxine maintenance dose and outcome19. Also the timing of 
treatment seems important. As delay in pyridoxine treatment probably worsens outcome. 
Finally, one Dutch young adult recently reported feelings of depression, which resolved after 
increase of her daily dose from 100 to 200 mg pyridoxine (unpublished data). Altogether, 
the current advised daily dose for pyridoxine is thus based on expert opinions with limited 
patients observations, without studies of the pyridoxine levels in the cerebrospinal fluid 
and without structured, prospective studies. Only recently normal values for cerebrospinal 
fluid B6 vitamers in preterms have been reported44. There have been no controlled trials in 
neonates with PDE that studied long-term outcome in relation to daily dose of pyridoxine. 
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These studies should be done and they should also study side effects of pyridoxine in PDE 
and non-PDE patients, as side effects have been reported35,45. Currently, it is assumed that 
patients with PDE should receive 15 mg/kg/day (maximum 150 mg/day) pyridoxine, and 
only in exceptional cases, e.g. with intractable seizures necessarily to reach and maintain 
seizure control, higher dosages seem warranted.
Antenatal start of treatment was associated with a favourable outcome23. The benefits of 
antenatal treatment were only studied in a few individual cases, and the results of these 
studies should be interpreted with caution. They provide, however, a reasonable argument 
to supplement mothers of PDE patients with pyridoxine during subsequent pregnancies, 
in order to prevent foetal and neonatal seizures, as well as birth-related complications, 
and improve neurodevelopmental outcome. The maternal advised daily doses should be 
50 to 100 mg daily. Maximal 100 mg because higher maternal doses of pyridoxine might 
potentially cause neuronal hyperexcitability in non-PDE neonates35.
It has long been thought that folinic acid responsive seizures and PDE were two separate 
but resembling disorders. However all patients diagnosed with folinic acid responsive 
seizures in the literature, have recently been shown, both biochemically and genetically, 
to suffer from antiquitine deficiency, i.e. PDE. This indicated that folinic acid can be of 
additional benefit in PDE patients, though the biochemical basis for this is unclear39. To 
date it is unclear why folic acid treatment is successful in some PDE patients. 
The treatment with pyridoxine compensates the chemical inactivation of PLP, but the 
accumulation of lysine degradation metabolites does not normalise24. These accumulating 
metabolites i.e. α-AASA, P6C and pipecolic acid are potentially neurotoxic compounds. 
The increased levels of lysine degradation metabolites might be responsible for the limited 
success of pyridoxine treatment, as about 75% of patients have developmental delay, 
30% need additional anti-epileptic drugs and progressive cerebral MRI abnormalities are 
observed in patients19. Standard dietary treatment for inborn errors of metabolism consists 
of substrate reduction. For instance in glutaric aciduria type I, also an inborn error of the 
degradation of lysine, prognosis can be improved with a diet low in lysine and with carnitine 
supplementation. So for PDE, dietary lysine reduction can reduce accumulation of lysine 
substrates and this might improve outcome. The first observational study on dietary lysine 
restriction presented hopeful results24. The diet was well tolerated with good compliance, 
no side effects were reported. Reduced levels of lysine metabolites were measured in 
all patients. Seizure control and improvement of age-appropriated skills was observed in 
most. So additional treatment with a lysine restricted diet is hopeful but before such a diet 
therapy becomes a mainstay of treatment, more evidence has to be generated.
Because of the rarity of PDE, international collaboration is necessary, since only 
international, multi-centre collaboration might result in studied cohort sizes which allow firm 
evidence. These studies need modern methodologies which permit firm statistical relevant 
conclusions. The endpoint of such studies should be focused on developmental outcome. 
The requirements for such studies are funding, a structured international database, and a 
medical ethical approved research protocol. 
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In 2003 Baxter reported that PDE remained a clinical and biochemical conundrum. In the 
last years important progress has been made to understand PDE. However, we can only 
state that this conundrum is partly unravelled and prognosis of children with PDE has not 
been improved. So we should continue our efforts and research to understand PDE and 
improve outcome. 
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Summary      
Pyridoxine Dependent Epilepsy (PDE, MIM#266100) is a rare autosomal recessive disorder. 
In most patients PDE is characterized by neonatal seizures that do not respond to classic 
anti-epileptic drugs but do respond after supplementation of pyridoxine. 
From 2006 two Dutch groups, under the leadership of Prof. Dr. Michèl Willemsen, 
Department of Pediatric Neurology, Radboud University Nijmegen, Medical Centre, 
Nijmegen and Prof. Dr. Cornelis Jakobs, Metabolic Unit, Department of Clinical Chemistry, 
VU University Medical Centre, Amsterdam collaborated on a PDE research project. In this 
thesis we studied epidemiological, biochemical, molecular genetic and clinical aspects 
(diagnostic and outcome) of the Dutch PDE patients (11 patients in 2005; and 22 patients 
in 2012). 
Epidemiologic data on PDE are scarce and national data were only available from the 
UK and Ireland (1:783 000). In 2005, we studied the epidemiology of PDE based upon 
clinical criteria in the Netherlands (Chapter I.b). Nationwide all departments of paediatrics 
(n = 113; response rate 67%) and departments of paediatric or neonatal neurology 
(n = 17; response rate 94%) were asked to report patients with PDE. Thirteen patients 
were reported and we classified them as having definite (n = 4), probable (n = 3), or as 
possible (n = 4) PDE. Two patients did not meet clinical criteria for either of these groups. 
Based on these data, a birth incidence of PDE in the Netherlands was calculated to be 
1:396 000 for definite and probable cases, and 1:252 000 when possible cases were 
also included. The study showed that the diagnosis in the past was often made without 
performance of a formal ‘trial of withdrawal’. We concluded that regional differences in 
diagnostic skills were unlikely to account for the different incidences. It was postulated that 
a founder effect in the Netherlands might explain the difference in birth incidence between 
the United Kingdom and the Netherlands. Furthermore, it seemed quite reasonable to us 
to assume that some patients with PDE may never have been recognised, i.e. diagnosed, 
and (thus) may have missed the chance to be treated appropriately. At that moment we 
concluded that a better knowledge of the disease entity and the clinical criteria needed 
for establishment of the diagnosis, as well as better understanding of the underlying 
disease mechanism, would contribute to increased awareness, earlier diagnosis, and more 
adequate management of PDE. 
After completion of this epidemiological study the metabolic mechanism of PDE was 
elucidated. In 2006, α-aminoadipic semialdehyde (α-AASA) dehydrogenase deficiency was 
identified as the cause of PDE (Mills 2006). In 2007, Chapter II.a, we re-evaluated the 
series of clinically diagnosed Dutch PDE patients described in Chapter I.b, by measuring 
α-AASA and PA levels in urine and plasma. In all patients with clinically definite PDE, and 
in most patients with probable or possible PDE, the clinical diagnosis of PDE could be 
confirmed at the metabolite level. This study confirmed that non-invasive urinary screening 
for α-AASA provides a reliable tool to diagnose PDE. 
In Chapter II.b the reference values for urinary P6C and α-AASA were determined. 
We studied 91 urine samples from neonates admitted to a level IIIa NICU in Veldhoven, 
Chapter V
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the Netherlands. Additional we studied 100 urine samples in older children, to establish 
reference values for α-AASA and P6C for all age groups. Urinary concentrations of P6C and 
α-AASA values correlated positively with protein intake, and negatively with gestational 
age and body weight, no correlation with gender or any studied neonatal IC condition or 
treatment was found.
After 2006 the assessment of urinary α-AASA is the diagnostic laboratory test for PDE. 
α-AASA is in spontaneous equilibrium with its cyclic form Δ1-piperideine-6-carboxylate 
(P6C). Ongoing diagnostic screening and monitoring revealed that in some individuals, 
with apparently milder ALDH7A1 variants, and patients co-treated with a lysine restricted 
diet, urinary α-AASA was only modestly increased. This prompted us to investigate the 
diagnostic power and added value of the assessment of urinary P6C, as P6C measurement 
is easier to perform, compared to α-AASA (Chapter II.b). In all 40 urine samples from 35 
individuals with proven PDE, we detected increased levels of P6C. Therefore, we concluded 
that the diagnostic strength of the assessment of urinary P6C and α-AASA is comparable. 
Following the first identification of pathogenic mutations in the α-AASA dehydrogenase 
(ALDH7A1, Antiquitin) gene in 2006, we analyzed the DNA of the Dutch biochemically proven 
PDE patients (Chapter II.c). We identified three different mutations in the Dutch patients: 
the common c.1195G > C, p.Glu399Gln mutation; a novel missense mutation (c.1348T > A; 
p.Cys450Ser) and an intriguing “silent” mutation (c.750G > A; p.Val250GlyfsX23) in 
ALDH7A1. We concluded that the high incidence of the c.1195G > C mutation is a strong 
argument for a founder effect in the Netherlands - as we had postulated in 2005, Chapter 
I.b. This study also illustrates the importance of mRNA studies when a seemingly non-
pathogenic or ‘silent’ variant is detected, especially when increased urinary levels of 
α-AASA are measured without the identification of causative mutations in the ALDH7A1 
gene.
Because of the rarity of PDE clinical cohort studies in PDE are uncommon, as they take 
great effort to collect data. Only 200 patients have been described in literature, in about 
130 reports (Stockler 2012) and most reports describe less than 5 patients, which limits 
conclusions.
Prompt recognition and treatment of PDE is probably important for prognosis. We studied 
immediate EEG alterations in neonates following intravenous pyridoxine, Chapter III.a. 
Our hypothesis was that in neonatal Therapy Resistant Seizures (TRS), direct EEG alterations 
would discriminate PDE from non-PDE patients. In ten neonates with TRS (6 PDE, 4 non-
PDE), we compared on-line EEG alterations by pyridoxine-IV. EEG segments were visually 
and digitally analyzed for average background amplitude and total- and relative- power. In 
3 of 10 (2/6 PDE and 1/4 non-PDE neonates), pyridoxine-IV caused flattening of the EEG 
amplitude and attenuation of epileptic activity. Quantitative EEG alterations by pyridoxine-
IV consisted of EEG responses (p < 0.05), similar in PDE and non-PDE for central amplitude, 
total power and relative power. In conclusion, our hypothesis had to be rejected, as in 
neonatal TRS, pyridoxine-IV induces non-specific EEG responses that neither identify nor 
exclude PDE. Pyridoxine supplementation should be continued in neonates with TRS until 
PDE is diagnosed or excluded by metabolic and/or DNA analysis.
Summary 
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In Chapter III.b we studied the effects of antenatal treatment in PDE as incidental reports 
suggested that antenatal treatment of PDE may improve neurodevelopmental outcome. 
Two families with PDE are reported. Antenatal treatment was instituted during the second 
pregnancy in each family (50 and 60 mg pyridoxine daily from 3 and 10 weeks of gestation, 
respectively). Perinatal characteristics and neurodevelopmental outcome were compared 
between the untreated and treated child within each family. Meconium stained amniotic 
fluid was present in both first pregnancies and abnormal foetal movements were noticed 
in one. In the treated infants, pregnancy and birth were uncomplicated and neonatal 
seizures were prevented. In family A, DQ was 73 and 98 in the antenatally untreated and 
treated child respectively. In family B, IQ’s with and without fetal therapy were 80 and 106 
respectively. 
The results presented in this study suggest that antenatal pyridoxine supplementation in 
selected families may be effective in preventing intrauterine seizures, decreasing the risk 
of complicated birth, and improving neurodevelopmental outcome in PDE. 
The aim of the study in Chapter III.c was to determine long-term developmental outcome 
and relating factors between patient characteristics and follow-up data. Fourteen patients 
were included (4 males, 10 females; 11 families; median age at assessment 6 years; 
range 2.5 – 16 years).Pyridoxine was started antenatally in two children, in the first week 
of life in five, in the first month of life in three, or after the first month of life (range 
2.5 – 8 months) in four. No children were physically disabled; however, only five walked at 2 
years of age. Mental development was delayed in most: median IQ or developmental index 
was 72 (SD 19). Pyridoxine controlled seizures in 10 of 14 children, four needed additional 
antiepileptic drugs. Seizure persistence, antiepileptic drugs (other than pyridoxine), EEG 
background, and epileptiform activity were not associated with outcome. On neonatal 
MRI, structural and white matter abnormalities occurred in five of eight children; on 
follow-up, the number of abnormal MRI findings had increased. Delayed initiation of 
pyridoxine medication and corpus callosum abnormalities were significantly associated 
with unfavourable neurodevelopmental outcome, but normal follow-up imaging did not 
predict a good outcome. These results make clear that the outcome for patients with PDE 
is still not favourable and that individual outcome cannot be predicted by the evaluated 
characteristics. 
In Chapter III.d we reported one PDE patient. On ophthalmoscopy on the 5th day bilateral 
multiple white centred retinal haemorrhages, so called Roth spots, were observed. These 
Roth spots disappeared after a few months. MRI of the brain showed an abnormal diffusion 
signal with increased Apparent Diffusion Coefficient and little blood around the tentorium. 
Roth spots are non-specific hemorrhagic signs that can occur in a variety of conditions 
of acute systemic insults in homeostasis, most often infections, which relate to retinal 
capillary damage and the ensuing reparative process – none were present in this patient. 
Further research is necessarily to determine whether Roth spots are a regular finding and 
related to PDE.
Chapter V
Boek_VB_bruin.indd   112 3-7-2013   20:50:19
113
Nederlandse samenvatting
Dankwoord 
Curriculum vitae
Addendum
Boek_VB_bruin.indd   113 3-7-2013   20:50:19
114
Addendum
Samenvatting    
Pyridoxine Afhankelijke Epilepsie, Pyridoxine Dependent Epilepsy (PDE, MIM#266100) 
is een zeldzame autosomaal recessieve aandoening. Bij de meeste patiënten wordt 
PDE gekenmerkt door convulsies (stuipen) bij pasgeborenen. Deze reageren niet op de 
anticonvulsieve medicijnen die gebruikt worden bij pasgeborenen maar verdwijnen wel na 
toediening van pyridoxine (= vitamine B6). 
Vanaf 2006 werken in Nederland twee groepen samen in hun wetenschappelijk onderzoek 
rond PDE. Eén onder leiding van Prof. Dr. Michèl Willemsen, Afdeling Kinderneurologie, 
Radboud Universiteit Nijmegen, Medisch Centrum, Nijmegen en de ander onder leiding van 
Prof. Dr. Cornelis Jakobs, Metabole Unit, Afdeling Klinische Chemie, VU Universitair Medisch 
Centrum, Amsterdam. In dit proefschrift werden de epidemiologische, biochemische, 
moleculair genetische and klinische aspecten (Diagnose en Prognose) van de Nederlandse 
PDE patiënten (11 patiënten in 2005; 22 patiënten in 2012) beschreven. 
Epidemiologische data met betrekking to PDE zijn schaars gepubliceerd. Nationale data 
zijn alleen vanuit Engeland en Ierland (1:783 000) gemeld. In 2005, bestudeerden wij de 
epidemiologie van PDE, gebaseerd op klinische kenmerken in Nederland (Chapter I.b). 
Schriftelijk werden alle kinderafdelingen (n = 113; response 67%) en alle kinderneurolo-
gische afdelingen (n = 17; response 94%) gevraagd hun PDE patiënten te melden. 
Dertien patiënten werden gemeld en zij werden door ons geclassificeerd als ‘definite’ 
(n = 4), ‘probable’ (n = 3), of ‘possible’ (n = 4) PDE patiënt. Twee patiënten voldeden aan 
geen van de gestelde klinische criteria. Op basis van deze data werd een geboorte incidentie 
voor Nederland berekend van 1 op 396 000 voor ‘definite’ en ‘probable’ PDE, en van 1 op 
252 000 als ook de kinderen met ‘possible’ PDE worden geïncludeerd. Deze studie liet zien 
dat de diagnose PDE in het verleden vaak was gesteld zonder een formele ‘trial of withdrawal’. 
Tevens werd geconcludeerd dat landelijke verschillen in diagnostische skills waarschijnlijk 
niet de verklaring zijn voor de gevonden verschillen in incidentie tussen de verschillende 
landen. Het verschil in geboorte incidentie tussen Nederland en Engeland is mogelijk te 
verklaren door een ‘founder’ effect in Nederland. Het leek ons verder aannemelijk dat 
sommige patiënten nooit worden herkend en dus nooit worden gediagnosticeerd met PDE, 
en derhalve niet de kans hebben om een adequate medische behandeling te ontvangen. 
De conclusie van de studie was dat een betere kennis van de klinische criteria van PDE, 
alsook een beter begrip van de onderliggende ziekte mechanismen, zou kunnen leiden tot 
een hogere alertheid voor PDE, een vroegere diagnose en een adequate behandeling. 
Na publicatie van deze epidemiologische studie werd het metabole defect van PDE gevonden. 
Een tekort van het enzym α-aminoadipine semialdehyde (α-AASA) dehydrogenase in het 
lysine metabolisme, bleek verantwoordelijk voor PDE (Mills 2006). Daarna, Chapter II.a, 
herevalueerden wij de patiënten met klinisch gediagnosticeerd PDE, Chapter I.b, door bij 
deze patiënten het α-AASA en het pipecoline zuur in urine en plasma te meten. Bij alle 
patiënten met ‘definite’ PDE en bij de meeste patiënten met ‘probable’ of ‘possible’ PDE, 
kon de klinische diagnose van PDE worden bevestigd door middel van metabool onderzoek. 
Deze studie bevestigde dat non-invasief urine onderzoek van α-AASA, een betrouwbare 
methode is om PDE te diagnostiseren. 
Boek_VB_bruin.indd   114 3-7-2013   20:50:19
115
In Chapter II.b worden de referentie waarden voor P6C en α-AASA in de urine beschreven. 
Hiervoor werden 91 urine monsters van pasgeborenen die waren opgenomen op de NICU 
in Veldhoven onderzocht. Om de leeftijd specifieke referentie waarden voor α-AASA and 
P6C te bepalen werden 100 urine monsters onderzocht van oudere kinderen. De urine 
waarden voor P6C en α-AASA zijn positief gecorreleerd met eiwit intake en negatief met 
zwangerschapsduur en lichaamsgewicht. Geen correlatie werd gevonden met geslacht of 
neonatale Intensive Care aandoening. 
Sinds 2006 is de bepaling van α-AASA in urine, de diagnostische laboratorium test voor 
PDE. α-AASA blijkt in spontaan evenwicht te zijn met zijn cyclische vorm Δ1-piperideine-
6-carboxylate (P6C). Inmiddels blijkt dat sommige kinderen, mogelijk kinderen met een 
mildere ALDH7A1 variant, en kinderen met een lysine beperkt dieet, dat in de urine soms 
slechts licht verhoogde α-AASA waarden worden gevonden. Daarom werd besloten te 
onderzoeken wat de toegevoegde waarde is van de urine bepaling van P6C, omdat deze 
bepaling gemakkelijker is te verrichten is dan de meting van α-AASA. In 40 urine monsters 
van 35 PDE patiënten, werden vergelijkbare verhoogde waarden van P6C gemeten. Er 
werd daarom geconcludeerd dat de diagnostische waarde van P6C en α-AASA in urine 
vergelijkbaar is.
Na de identificatie van de pathogene mutaties in het α-AASA dehydrogenase (ALDH7A1, 
Antiquitin) gene in 2006, werd het DNA van de Nederlandse patiënten met biochemisch 
bewezen PDE (Chapter II.c) geanalyseerd. Bij de Nederlandse patiënten werden drie 
verschillende mutaties gevonden: de in Nederland frequente c.1195G > C, p.Glu399Gln 
mutatie; een nieuwe ‘missense’ mutatie (c.1348T > A; p.Cys450Ser) en een “silent” mutatie 
(c.750G > A; p.Val250GlyfsX23) in het ALDH7A1 gen. Er werd geconcludeerd dat de 
hoge incidentie van de c.1195G > C mutatie een sterke aanwijzing is voor een ‘founder’ 
effect in Nederland – zoals reeds eerder was gepostuleerd in 2005, Chapter I.b. Deze 
studie illustreert ook het belang van mRNA studies bij de vondst van ogenschijnlijke niet-
pathogene of ‘silent’ varianten, met name als verhoogde urine waarden worden gemeten 
van α-AASA, zonder de identificatie van verklarende pathogene mutaties in het ALDH7A1 
gen.
Klinische cohort studies van PDE patiënten zijn nauwelijks gepubliceerd, omdat PDE zeer 
zeldzaam is en omdat het een grote inspanning vergt om voldoende data te verzamelen. 
Slechts 200 patiënten zijn beschreven in de literatuur in ongeveer 130 studies (Stockler 
2012) en de meeste studies beschrijven minder dan 5 patiënten, hetgeen de conclusies 
per studie beperkt. 
Directe herkenning en behandeling van PDE lijkt belangrijk voor de prognose. De EEG 
veranderingen bij pasgeborenen direct na intraveneuze (IV) toediening van pyridoxine 
werd bestudeerd, Chapter III.a. De hypothese was dat bij kinderen met neonatale 
Therapie Resistente Stuipen (TRS), directe EEG veranderingen het onderscheid mogelijk 
zou maken tussen PDE en niet-PDE patiënten. Bij tien pasgeborenen met TRS (6 PDE, 4 
niet-PDE), werden de directe online EEG veranderingen na pyridoxine–IV vergeleken. EEG 
segmenten werden visueel en digitaal geanalyseerd, gericht op gemiddelde achtergrond, 
en totale- en relatieve- power. Bij 3 van de 10 pasgeborenen (2 van de 6 PDE plus 1 
Nederlandse samenvatting
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van de 4 niet-PDE pasgeborenen), veroorzaakte pyridoxine-IV afvlakking van de EEG 
amplitude en verdwijnen van de epileptische activiteit. Kwantitatieve EEG veranderingen 
voor zowel centrale amplitude, totale power en relatieve power, direct na pyridoxine-IV 
veroorzaakte een EEG respons (p < 0,05), die vergelijkbaar was tussen PDE en niet–
PDE pasgeborenen. Uit dit onderzoek werd geconcludeerd dat het niet mogelijk is PDE 
of niet-PDE te onderscheiden op basis van de EEG respons na pyridoxine. Derhalve moet 
pyridoxine toediening worden gecontinueerd bij pasgeborenen met TRS totdat PDE is 
eëxcludeerd door middel van metabool en of DNA onderzoek. 
In Chapter III.b werden de effecten van antenatale behandeling bij PDE bestudeerd. 
Sommige studies suggereerden namelijk dat antenatale behandeling de psychomotore 
ontwikkeling van PDE patiënten zou kunnen bevorderen. In 2 families met eerder een kind 
met PDE kreeg de moeder tijdens deze tweede zwangerschap, respectievelijk dagelijks 
50 en 60 mg pyridoxine vanaf de 3e respectievelijk de 10e zwangerschap week. Na 
de geboorte werd bij deze tweede kinderen PDE geconstateerd middels een verhoogd 
α-AASA. Binnen één gezin werden de perinatale karakteristieken en de psychomotore 
uitkomst vergeleken tussen het kind dat wel en het kind dat niet antenataal behandeld 
was. Meconium houdend vruchtwater was aanwezig bij beide eerste zwangerschappen 
en abnormale kindsbewegingen werden opgemerkt door één moeder. Bij de behandelde 
kinderen was de zwangerschap en geboorte ongecompliceerd en neonatale stuipen werden 
voorkomen. Bij familie A was het IQ respectievelijk 73 en 98 bij het antenataal niet en het 
antenataal wel behandelde kind. In familie B was het IQ respectievelijk 80 en 106. 
De resultaten van deze studie suggereren dat antenatale pyridoxine behandeling in 
geselecteerd families effectief zou kunnen zijn om intra-uteriene stuipen te voorkomen, 
het risico op een geboorte complicatie te verminderen en de psychomotore ontwikkeling 
van het kind te verbeteren.  
Het doel van de studie in Chapter III.c was om te bepalen wat de psychomotore 
ontwikkeling op de lange termijn is en welke factoren hierbij van invloed zijn. Veertien 
patiënten deden mee aan het onderzoek (4 jongens en 10 meisjes; 11 families; mediane 
onderzoeksleeftijd was 6 jaar; spreiding van 2,5 tot 16 jaar). Pyridoxine was antenataal 
gestart bij twee kinderen (Chapter II.b), in de eerste levensweek bij vijf, in de eerste 
levensmaand bij drie of gestart na de eerste levensmaand bij vier kinderen (spreiding 2,5 
tot 8 maanden). Geen van de kinderen was lichamelijke gehandicapt; maar slechts vijf 
kinderen konden los lopen op de leeftijd van 2 jaar. De mentale ontwikkeling was vertraagd 
bij de meeste kinderen: het mediane IQ of ontwikkeling index was 72 (SD 19). Pyridoxine 
controleerde de convulsies bij 10 van de 14 children, vier kinderen hadden additionele 
anti-epileptische medicijnen nodig. Blijvende convulsies, het gebruik van anti-epileptische 
medicijnen (anders dan pyridoxine), EEG achtergrond patroon en EEG epileptiforme 
activiteit waren niet geassocieerd met de psychomotore ontwikkeling. Op de neonatale 
MRI werden structurele afwijkingen en witte stof afwijkingen gezien bij vijf van de acht 
kinderen; bij follow-up was het aantal abnormale MRI bevindingen toegenomen. Late 
pyridoxine behandeling en Corpus Callosum afwijkingen waren significant geassocieerd 
met een ongunstige psychomotore ontwikkeling, maar een normale MRI bij follow-up 
voorspelde geen ongestoorde psychomotore ontwikkeling. Deze resultaten maken duidelijk 
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dat de prognose van kinderen met PDE nog steeds niet goed is en dat de individuele 
ontwikkeling niet voorspeld kan worden. 
In Chapter III.d wordt één PDE patiënt beschreven met bilateraal multiple retina 
bloedingen met een wit centrum gezien, zogenaamde Roth spots. Geleidelijk verdwenen 
deze Roth spots na een paar maanden. MRI van de hersenen toonde een abnormaal diffusie 
signaal met verhoogd Apparent Diffusion Coefficient en wat bloed rond het tentorium. 
Roth spots zijn niet-specifieke bloedinkjes welke bij verschillende aandoeningen kunnen 
ontstaan waarbij sprake is van een plotse systemische verandering in de homeostase, 
meestal betreft dit infecties, die gerelateerd zijn met beschadigingen van het retinale 
capillaire vaatbed en het aansluitende lokale genezingsproces in de retina. Geen van 
de bekende geassocieerde aandoening was aanwezig bij deze PDE patiënt. Mogelijk zijn 
Roth spots geassocieerd met PDE, verdere research is nodig om te bepalen of Roth spots 
regelmatig gevonden worden bij PDE en wat de relatie is met PDE.
Nederlandse samenvatting
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De weg van de wetenschap is als het leven. Ga elke dag op stap met een doel, vastberaden, 
met geduld en passie. Gestaag zul je je doel bereiken. Op de reis van dit onderzoek heb ik 
mij nooit gehaast en vooral genoten van alle plekken waar ik geweest ben. En ik verheug 
mij op de plekken waar ik ooit nog hoop te komen. Samen kom je ergens, alleen bereik je 
niks. Een ieder die ik op mijn reis ben tegen gekomen en die mij geholpen heeft wil ik bij 
deze bedanken, mij realiserende dat mijn reis in Pyridoxine Afhankelijke Epilepsie nog niet 
afgelopen is. Er zijn te veel mensen die ik moet en wil bedanken en helaas zal ik ook velen 
vergeten, waarvoor mijn excuses. Enkelen wil ik toch met nadruk bedanken.
Beste Michèl, Prof. Dr. M.A. Willemsen. In 2006 kon ik na jouw telefoontje niet bevroeden 
waar ik zou komen, alhoewel jij meteen benadrukte dat op dit onderwerp een promotie 
mogelijk zou zijn. Ik dank je voor je integere steun en uitstekende hulp op de momenten 
dat ik die nodig had. Jij begrijpt waar mijn talenten liggen en wat mijn verbeterpunten 
zijn. Mijn dank. Ook ging jij op de juiste momenten in de wind staan om één en ander te 
regelen, zodat ik in de luwte verder kon werken aan de inhoud van dit boekje. Gaarne heb 
ik gewacht zodat jij mijn promotor zou kunnen zijn. Ik hoop dat we in de komende jaren 
verder kunnen blijven samenwerken aan de pyridoxine problematiek.
Prof dr C Jakobs, beste Karel. Dank dat ik, als buitenstaander in jullie topkeuken van de 
metabole ziekten heb mogen werken. Ik was altijd weer verbaasd hoe groot jullie inzicht 
is in de biochemische mechanismen van dit ziektebeeld. Het is voor mij een eer dat ik als 
één der laatste bij jou mag promoveren.
Dr. E Struijs, beste Eduard. Regelmatig hebben we gesproken over AASA en pipecolinezuur, 
maar bovenal praten we graag over snoeken. De uitspraak ‘Je moet vissen anders kun 
je niet vangen’ gaat niet over vissen maar over onze gemeenschappelijke attitude in het 
leven, blijf bezig en je zult inzichten opdoen en verbeteringen vinden. 
Dr J. Been, beste Jasper, dankzij jou heb ik mijn plekje gekregen op de weg van onderzoek. 
Samen hadden we een idee. Ik bepaalde een koers en jij zorgde er voor dat we op de weg 
bleven. Samen kwamen we aan bij ons reisdoel. Dank dat ik met jou heb mogen samen 
werken.
Dr. D Sival, beste Deborah, groot is mijn dank hoe goed jij kunt ‘kleien’. Ik heb dat talent 
niet, laat staan het geduld. Zonder jouw hulp was het hoofdstuk over het neonatale EEG 
nooit geworden wat het nu is. 
Lucas Dijck, dank voor je hulp bij het bestuderen van de EEG’s. Maar bovenal dank voor 
gesprekken en de kop koffie die ik met jou mocht drinken. 
Beste Feico en Whalter. Beste collega’s. Dank voor jullie hulp in de voorbereiding 
respectievelijk de afronding van meerdere manuscripten. Dank ook hoe jullie mijn 
paranimfale-dilemma hebben opgelost. Ik hoop nog jaren intensief met jullie te mogen 
samenwerken in Veldhoven.
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Beste Saskia Houterman, mijn dank is groot hoe jij met flair, mij door de lastige epidemiologie 
hebt geleid. 
Alle kinderneurologen en alle neonatologen in Nederland, klinische chemie MMC, collega 
kinderartsen, secretariaat dank voor alle data die ik met jullie directe of indirecte hulp 
mocht verzamelen en voor jullie geduld dat ik jaren lang op dinsdag ochtend probeerde 
een stap voorwaarts te maken in dit onderzoek. Beste Francien, bovenstaande is natuurlijk 
bovenal voor jou van toepassing.
Beste Ouders en kinderen met pyridoxine afhankelijke epilepsie, dank voor al jullie niet 
aflatende medewerking en dank voor het vertrouwen dat ik van jullie heb mogen ontvangen. 
Mijn ouders wil ik danken voor alles kansen die zij voor ons kinderen hebben gecreëerd. 
Ik dank mijn broer en zussen voor de lol in de familie en de kracht die we gezamenlijk 
kunnen ontwikkelen. 
Ine, Anita, Suzanne, Pa, schoonouders. Graag had ik jullie op deze dag aanwezig gezien. 
Dagelijks zijn onze gedachten bij jullie.
Lieve Marita, Rosalie, Benjamin, Gidius, wat zou ik zijn zonder jullie. Marita, mijn dank 
is groot voor je liefde voor mij. Al ben ik een gewone man, ‘behind me, there is a great 
woman’. Rosalie, Benjamin, Gidius, niks is teveel om voor jullie te doen. Van harte hoop 
ik dat jullie je talenten ten volle kunnen ontwikkelen. Ik hoop dat we nog 1000 zondag-
ochtend-ontbijtjes mogen hebben. 
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Levinus Adrianus (roepnaam Vinus) Bok, werd op 26 april 1958 geboren in de Noord 
Oostelijke Polder. Zijn ouders, Wijnand Bok en Truus Bok - van Eeten zijn één van de 
pioniers van de Noord Oost Polder en kregen zes kinderen. Hij had een gelukkige jeugd 
en was voorbestemd om de boerderij van zijn vader te continueren. Echter, de studie 
geneeskunde leek hem meer te passen. Na het behalen van het Havo- en het VWO- diploma 
in respectievelijk 1976 en 1978 deed hij zijn eerste jaar geneeskunde
aan de Universiteit van Amsterdam. Deze studie werd verder voortgezet in Groningen. 
Na een onderbreking van een jaar in verband met een wereldreis rondde hij de studie 
af in april 1986 in Groningen. Tijdens de co-schappen in Deventer was de belangstelling 
gegroeid voor kindergeneeskunde (Dr. J. van der Vlugt en Drs. H. Holl), wat vorm gegeven 
werd door een afstudeer project ‘biochemische kenmerken van neuroblastoom patiënten’ in 
het Emma Kinder Ziekenhuis in Amsterdam ( Prof. Dr. P.A. Voute en Drs. N. Abeling, hoofd 
biochemie). Vanaf 1986 was hij werkzaam als arts-assistent kindergeneeskunde in de 
Weezenlanden te Zwolle (Hoofd: Dr. F. van de Logt) en vanaf 1987 in het Wilhelmina Kinder 
Ziekenhuis te Utrecht (Hoofd: Prof. Dr. J.L. Van de Brande; Mentor Dr. J. Roord). In april 
1988 werd begonnen met de specialistenopleiding kindergeneeskunde in het Academisch 
Ziekenhuis Nijmegen (Opleiders: Prof. Dr. G.B. Stoelinga en Prof. Dr. R.C. Sengers), en 
later het Joseph Ziekenhuis te Veldhoven (Opleider: Dr. E. Lommen). In 1991 en 1992 was 
hij voorzitter van de Junior Afdeling Kindergeneeskunde. 
In 1993 startte hij de werkzaamheden als kinderarts in Lelystad. Sinds 2001 is hij werkzaam 
in het Màxima Medisch Centrum in Veldhoven. Een deeltijd opleiding in de kinderneurologie 
werd gevolgd in 2001 en 2002 (programma samensteller Prof. Dr. J Rotteveel). Van 2002 
tot 2005 was hij voorzitter van de vakgroep Kindergeneeskunde van het Màxima Medisch 
Centrum. Tevens was hij vanaf 2008 co-assistent opleider kindergeneeskunde, en vanaf 
2013 waarnemend arts-assistent opleider. 
De werkzaamheden voor het onderzoek van dit proefschrift startten in 2006, ‘deze reis lijkt 
nu ten einde’. Het volgende reisdoel is de toepassing van de opgedane kennis in een betere 
therapie van PDE, gefocust op beperking van het eiwit lysine in het dieet en optimalisering 
van de pyridoxine dosering.
Vinus is gelukkig getrouwd met Marita Cals. Samen zijn zij de trotse ouders van Rosalie, 
Benjamin en Gidius Bok.
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Andere Publicaties, waarvan PDE gerelateerd (vet gedrukt):
1. Bok LA, Semmekrot BA, Monnens LAH. Symptomatologie en behandeling van neonatale hypertensie. 
Ned Tijdschr Kinderg 1992; 60:44-48
2. Umans-Eckhausen M, Bok V, Mahieu H, Haasnoot K. A neonate with respiratory distress after a traumatic 
delivery. Eur J Pediatr 1997; 156:891-892
3. Bok L, Wilde A, Lubbers W, Lange van I. A family with Ventricular Dysrhythmia, Brachytelephalangy, 
Camptodactyly and Facial Dysmorphisms. Abstract. PACE 1997; 20:2140
4. Giordano PC, Harteveld CL, Bok V, Delft van P, Batelaan D, Breslau-Siderius EJ, Bernini LF. A complex 
hemoglobinopathy diagnosis in a family with both beta-0 and alfa 0/+ Thalassemia homozygosity. Eur 
J Hum Gen 1999; 7:163-168
5. Vreken P, Bok LA, Gregersen N, Ruiter JPN, Denis S, IJlst L, Wijburg FA, Waterham HR, Wanders RJA. 
Biochemical and genetic studies in a family with short-chain acyl-CoA dehydrogenase deficiency. J. 
Inherit. Metab. Dis 2000;23(suppl.1):248-P.
6. Leyten CCM, Hugtenburg JG, Bok LA, Schobben AFAM. Epilepsie bij kinderen; de behandeling van 
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9. De Vries LS, Gunardi, Barth PG, Bok LA, Verboon-Maciolek, Groenendaal F. The spectrum of cranial 
ultrasound and magnetic resonance imaging abnormalities in congenital cytomegalovirus infection. 
Neuropediatrics 2004; 35:113-119
10. Eduard Struys, Karel Jacobs, Levinus Bok, Michel Willemsen. Enzymdefect veroorzaakt 
epilepsie. Episcoop 2006 sept; 14:3:29
11. Bok LA, Struys E, Willemsen MA, Been JV, Jakobs C. Pyridoxine Afhankelijke epilepsie. 
Tijdschrift voor Neurologie en Neurochirurgie 2007; 108(2):51-56
12. Maingay-de Groof F, Lequin MH, Roofthooft DW, Oranje AP, de Coo IF, Bok LA, van der Spek PJ, Mancini 
GM, Govaert PP.IExtensive cerebral infarction in the newborn due to incontinentia pigmenti.Eur J 
Paediatr Neurol. 2008 Jul; 12(4):284-289
13. van Os E, Niemarkt HJ, Verreussel MJ, Cruysberg JR, Bok LA, Spruijt L. Two neonates with congenital 
aniridia: the necessity of genetic investigation. Ned Tijdschr Geneesk 2008 Mar; 152(10):569-573
14. Schreuder LT, Nijhuis-van der Sanden MW, de Hair A, Peters G, Wortmann S, Bok LA, Morava E. succesfull 
use of albuterol in a patient with central core disease and mitochondrial dysfunction. J Inherit Metab 
Dis 2010 may 5 [epub]
15. van der Palen RL, Bok LA. A boy with a red swelling of the lower leg. NTVG 2010;154:A549. 
16. Kusters MA, Jol-van der Zijde EC, van Tol MJ, Bolz AW, Bok LA, Visser M, de Vries E. Impaired avidity 
maturation after tetanus toxoid booster in children with Down syndrome. Pediatr Infect Dis J. 2011 Apr; 
30(4):357-359 
17. Bok LA, Halbertsma FJ. A girl with rapidly progressie ataxia. NTVG 2011; 155:A2166. 
18. van Gameren-Oosterom H, van Wouwe JP, Bok LA. Optimale medische begeleiding van kinderen met 
Downsyndroom. Praktische Pediatrie 2011; 4:220-225 
19. Maartens IA, Wassenberg T, Buijs J, Bok L, de Kleine MJ, Katgert T, Andriessen P. Neurodevelopmental 
outcome in full term newborns with refractory neonatal seizures. Acta Paediatr. 2012 (apr); 101(4) 
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Boek_VB_bruin.indd   122 3-7-2013   20:50:19
123
Curriculum Vitae
20. Schot MJ, Halbertsma FJ, Katgert T, Bok LA. Development of children with symptomatic hemorrhage 
born after vacuum extraction. J Child Neurol 2013; 28(4):520-523
21. Kroon E, Bok LA, Halbertsma F. Spontaneous perinatal epidural haemorrhage in a newborn. BMJ Case 
Rep 2012 Feb 21
22. Kusters MA, Bok VL, Bolz W, Huijskens E, Peeters M, de Vries E. Influenza A/H1N1 Vaccination response 
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